Compounds > niacinamide
Page last updated: 2024-10-19

niacinamide and Disease Exacerbation

niacinamide has been researched along with Disease Exacerbation in 293 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"To evaluate prospectively the efficacy and safety of sorafenib, which has been the first-line treatment for advanced hepatocellular carcinoma (HCC), in Japanese HCC patients (pts) with not only Child-Pugh (C-P) A class but also C-P B class."9.27A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. ( Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K, 2018)
"To evaluate safety and efficacy of combining sorafenib with transarterial chemoembolization in patients with advanced stage hepatocellular carcinomas (HCCs)."9.27Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. ( Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T, 2018)
"To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE)."9.24Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. ( Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A, 2017)
"Since the approval of sorafenib, no other agent has been proven to show survival benefits in clinical trials involving patients with advanced hepatocellular carcinoma (HCC) resistant to sorafenib."9.22Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2016)
"Results of previous study showed promising but short-lived activity of sorafenib in the treatment of patients with unresectable advanced and metastatic osteosarcoma."9.20Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. ( Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A, 2015)
"GIDEON is a non-interventional, prospective, international study that evaluated the safety of sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in daily clinical practice, including Child-Pugh B patients."9.20[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. ( Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A, 2015)
"Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation."9.20Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015)
" However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)."9.20Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015)
"This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy."9.19Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. ( Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M, 2014)
"Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials."9.19Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. ( Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA, 2014)
"Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma."9.19Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. ( Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX, 2014)
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab."9.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"Sorafenib and everolimus are both active against neuroendocrine tumors (NET)."9.17Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. ( Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E, 2013)
"This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma."9.17Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. ( Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y, 2013)
" The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection."9.16Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012)
"The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC."9.16Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."9.15Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
"In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease."9.14Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. ( Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB, 2010)
"To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)."9.14[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010)
"In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo."9.13Sorafenib in advanced hepatocellular carcinoma. ( Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S, 2008)
"Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC)."8.98Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. ( Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M, 2018)
"Transarterial chemoembolization (TACE) is the recommended treatment for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage, whereas sorafenib is an orally administered small molecule target drug for BCLC C-stage."8.98Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y, 2018)
"The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial."8.93Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. ( Lv, L; Mei, ZC; Zeng, J, 2016)
"The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC)."8.90Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. ( Miyahara, K; Nouso, K; Yamamoto, K, 2014)
"Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE)."8.90Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. ( Bie, P; Chen, X; Hu, P; Zhang, L, 2014)
"Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial."8.90Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, M; Han, GH; Yang, M; Yuan, JQ, 2014)
"The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial."8.90An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. ( Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y, 2014)
"By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine."8.89Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. ( Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ, 2013)
"This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of sorafenib according to its licensed indication for advanced hepatocellular carcinoma (HCC)."8.86Sorafenib for the treatment of advanced hepatocellular carcinoma. ( Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S, 2010)
" Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD."8.02Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021)
"Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy."7.88Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018)
"Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC)."7.88Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. ( Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ, 2018)
"The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib."7.88Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2018)
"We report an advanced HCC patient with many lung metastases who failed sorafenib treatment."7.88The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. ( Duo, J; Ma, X; Zhao, Y; Zhu, H, 2018)
"There are few efficacy and toxicity data on sorafenib for patients treated for hepatocellular carcinoma (HCC) who are not Caucasian or Asian."7.88Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. ( Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB, 2018)
"For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines."7.85Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. ( Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2017)
"The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors."7.85Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. ( Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH, 2017)
"Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression."7.85Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. ( Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A, 2017)
"Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive."7.85Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. ( Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC, 2017)
"Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial."7.85Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. ( Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y, 2017)
"To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib."7.85Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017)
"Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable."7.85Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. ( Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM, 2017)
"Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)."7.83Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016)
"Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma."7.83Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. ( Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016)
"To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions."7.83TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016)
"Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear."7.83The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. ( Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y, 2016)
"To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)."7.83Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016)
"Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009."7.83Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. ( Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016)
"Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma."7.83Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016)
"To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)."7.83Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016)
"A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma."7.83Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. ( Chan, AL; Leung, HW; Liu, CF, 2016)
"The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC)."7.83Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. ( De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H, 2016)
"Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment."7.83Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. ( Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T, 2016)
"Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)."7.83Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. ( Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O, 2016)
"Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)."7.83Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. ( Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016)
"The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012."7.81Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. ( Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K, 2015)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."7.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
"Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)."7.81Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015)
"Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC)."7.81Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. ( Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S, 2015)
"Sorafenib has been shown to significantly improve the overall survival of patients with advanced hepatocellular carcinoma (HCC)."7.81Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. ( Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J, 2015)
"While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs."7.81Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. ( Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y, 2015)
"To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed."7.81Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. ( Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K, 2015)
"Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)."7.81Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015)
"Sorafenib is a specific adenosine triphosphate-competitive RAF inhibitor used as a first-line treatment of advanced hepatocellular carcinoma (HCC)."7.81Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. ( Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS, 2015)
"Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits."7.81TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. ( Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J, 2015)
"The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified."7.80Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. ( Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."7.80Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."7.80Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS)."7.80Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N, 2014)
"Sorafenib is a promising drug for advanced hepatocellular carcinoma (HCC); however, treatment may be discontinued for multiple reasons, such as progressive disease, adverse events, or the cost of treatment."7.80Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ, 2014)
"We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC)."7.80Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M, 2014)
"To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma (HCC)."7.80Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M, 2014)
"Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)."7.80Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. ( Kudo, M; Shimada, M; Tanaka, K, 2014)
"Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma."7.80Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. ( Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L, 2014)
"Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)."7.79Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC, 2013)
"To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy."7.79Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. ( Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM, 2013)
"The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC)."7.79Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. ( He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB, 2013)
"Sorafenib, an oral multikinase inhibitor, was approved for the treatment of advanced hepatocellular carcinoma (HCC), but has not been adequately evaluated for safety and effectiveness in Japanese patients with advanced HCC."7.79Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. ( Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013)
"Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART)."7.79Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. ( Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U, 2013)
"To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib."7.79Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2013)
"Sorafenib plasma concentrations were determined by liquid chromatography, every 2 weeks, in consecutive hepatocellular carcinoma patients treated with sorafenib."7.78Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ( Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012)
"To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC)."7.78Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. ( Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W, 2012)
"Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)."7.78Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012)
"Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma."7.78Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. ( De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2012)
"Prospective randomized trials have proven that sorafenib is a valid treatment option for patients with advanced-stage hepatocellular carcinoma (HCC)."7.78Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? ( Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012)
"This study investigates the effectiveness and safety of sorafenib in a heterogeneous cohort of Child-Pugh A, B and C patients with advanced hepatocellular carcinoma in a clinical-practice scenario."7.78Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. ( Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012)
"To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)."7.78Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. ( Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M, 2012)
"The purpose of this study was to describe the computed tomography (CT) findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma and to correlate the findings to the overall survival (OS)."7.77Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. ( Choi, JI; Kim, MJ; Lee, JS; Park, JW, 2011)
"This study compared post-transplant outcomes of patients with hepatocellular carcinoma (HCC) who took sorafenib prior to orthotopic liver transplantation (OLT) with those patients who were not treated with sorafenib."7.77Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE, 2011)
"The purpose of this study was to evaluate the role of des-γ-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC)."7.77Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2011)
"A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC)."7.77Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. ( Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C, 2011)
"The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)."7.77AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011)
"The aim of this study was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC)."7.77Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y, 2011)
"An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)."7.76Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."7.76Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."7.76Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
"To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice."7.76Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010)
"To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment."7.76Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. ( Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2010)
"To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)."7.76[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010)
"This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection."7.75Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009)
" Shortly after chemotherapy with sorafenib [anti-vascular endothelial growth factor (VEGF)] was initiated, progressive renal impairment, hypertension, and nephrotic-range proteinuria developed."7.75Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. ( Jonkers, IJAM; van Buren, M, 2009)
"We investigated the effects of the novel multikinase inhibitor sorafenib, which inhibits tyrosine kinases as well as serine/threonine kinases, in comparison to imatinib, a tyrosine kinase inhibitor, on hemodynamics, pulmonary and right ventricular (RV) remodeling, and downstream signaling in experimental pulmonary hypertension."7.74Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. ( Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N, 2008)
"Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with."6.84Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017)
"Sorafenib was given orally at 200 mg BiD for 5 days every week; bevacizumab was administered 5 mg/kg intravenously every 14 days."6.79Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. ( Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J, 2014)
"Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis."6.79Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. ( Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V, 2014)
" Pharmacokinetic sampling was performed during cycle 1."6.78NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
" The most common severe adverse event probably related to sorafenib was diarrhea (12."6.77Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."6.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
"Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity."6.75Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. ( Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B, 2010)
"Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies."6.75A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. ( Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E, 2010)
"Sorafenib was the first drug that has shown to increase survival in patients with advanced hepatocelullar carcinoma with an adequate safety profile."6.53Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. ( Bruix, J; Reig, M; Ribeiro de Souza, A, 2016)
"Sorafenib is a potential rescue therapy in patients with TACE failure."5.46Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. ( Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY, 2017)
"The management of hepatocellular carcinoma (HCC) in elderly patients is significantly more complicated than in younger patients because of medical comorbidities, advanced status at diagnosis, reduced liver function and altered drug pharmacokinetics."5.39Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. ( Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2013)
"Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity."5.39Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. ( Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA, 2013)
"Sorafenib was approved for advanced HCC based on trials in patients with Child-Pugh class A."5.39Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. ( Byrne, M; Estfan, B; Kim, R, 2013)
"Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC."5.37Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. ( Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A, 2011)
"In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not received prior systemic therapy, received either oral sorafenib (400 mg twice daily) or placebo until radiological and symptomatic progression."5.35Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. ( Rimassa, L; Santoro, A, 2009)
"To evaluate prospectively the efficacy and safety of sorafenib, which has been the first-line treatment for advanced hepatocellular carcinoma (HCC), in Japanese HCC patients (pts) with not only Child-Pugh (C-P) A class but also C-P B class."5.27A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. ( Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K, 2018)
"To evaluate safety and efficacy of combining sorafenib with transarterial chemoembolization in patients with advanced stage hepatocellular carcinomas (HCCs)."5.27Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. ( Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T, 2018)
"To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE)."5.24Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. ( Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A, 2017)
"Since the approval of sorafenib, no other agent has been proven to show survival benefits in clinical trials involving patients with advanced hepatocellular carcinoma (HCC) resistant to sorafenib."5.22Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2016)
"Results of previous study showed promising but short-lived activity of sorafenib in the treatment of patients with unresectable advanced and metastatic osteosarcoma."5.20Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. ( Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A, 2015)
"GIDEON is a non-interventional, prospective, international study that evaluated the safety of sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in daily clinical practice, including Child-Pugh B patients."5.20[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. ( Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A, 2015)
"Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation."5.20Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015)
" However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)."5.20Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015)
"This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy."5.19Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. ( Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M, 2014)
"Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials."5.19Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. ( Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA, 2014)
"Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma."5.19Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. ( Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX, 2014)
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab."5.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"Sorafenib and everolimus are both active against neuroendocrine tumors (NET)."5.17Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. ( Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E, 2013)
"This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma."5.17Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. ( Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y, 2013)
" The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection."5.16Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012)
"The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC."5.16Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."5.15Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
" Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma."5.15Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. ( Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O, 2011)
"In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease."5.14Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. ( Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB, 2010)
"To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)."5.14[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010)
"In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo."5.13Sorafenib in advanced hepatocellular carcinoma. ( Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S, 2008)
"Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC)."4.98Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. ( Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M, 2018)
"Transarterial chemoembolization (TACE) is the recommended treatment for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage, whereas sorafenib is an orally administered small molecule target drug for BCLC C-stage."4.98Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y, 2018)
"The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial."4.93Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. ( Lv, L; Mei, ZC; Zeng, J, 2016)
"Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma."4.91Refining sorafenib therapy: lessons from clinical practice. ( Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F, 2015)
"In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date."4.91[Advanced hepatocellular carcinoma: importance of clinical trials]. ( Aedo, V; Cristina, V; Faivre, S; Raymond, E, 2015)
"A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial."4.90Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. ( Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y, 2014)
"The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC)."4.90Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. ( Miyahara, K; Nouso, K; Yamamoto, K, 2014)
"Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE)."4.90Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. ( Bie, P; Chen, X; Hu, P; Zhang, L, 2014)
"Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial."4.90Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, M; Han, GH; Yang, M; Yuan, JQ, 2014)
"The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial."4.90An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. ( Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y, 2014)
"By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine."4.89Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. ( Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ, 2013)
"This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of sorafenib according to its licensed indication for advanced hepatocellular carcinoma (HCC)."4.86Sorafenib for the treatment of advanced hepatocellular carcinoma. ( Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S, 2010)
" Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD."4.02Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021)
"Oxaliplatin-based chemotherapy is an alternative systemic treatment for patients with metastatic hepatocellular carcinoma (HCC) who were refractory or intolerant to sorafenib."3.88Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. ( Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS, 2018)
"Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy."3.88Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018)
"Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC)."3.88Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. ( Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ, 2018)
"The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib."3.88Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2018)
"We report an advanced HCC patient with many lung metastases who failed sorafenib treatment."3.88The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. ( Duo, J; Ma, X; Zhao, Y; Zhu, H, 2018)
"There are few efficacy and toxicity data on sorafenib for patients treated for hepatocellular carcinoma (HCC) who are not Caucasian or Asian."3.88Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. ( Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB, 2018)
"For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines."3.85Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. ( Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2017)
"The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors."3.85Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. ( Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH, 2017)
"Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression."3.85Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. ( Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A, 2017)
"Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive."3.85Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. ( Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC, 2017)
"Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial."3.85Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. ( Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y, 2017)
"To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib."3.85Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017)
"Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable."3.85Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. ( Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM, 2017)
"Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)."3.83Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016)
"Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma."3.83Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. ( Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016)
"To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions."3.83TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016)
"Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear."3.83The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. ( Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y, 2016)
"To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)."3.83Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016)
"Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009."3.83Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. ( Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016)
"Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma."3.83Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016)
"To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)."3.83Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016)
"A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma."3.83Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. ( Chan, AL; Leung, HW; Liu, CF, 2016)
"The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC)."3.83Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. ( De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H, 2016)
"Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment."3.83Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. ( Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T, 2016)
"Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)."3.83Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. ( Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O, 2016)
"Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)."3.83Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. ( Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016)
"Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial."3.83Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. ( Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O, 2016)
"The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012."3.81Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. ( Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K, 2015)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."3.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
"Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)."3.81Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015)
"Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC)."3.81Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. ( Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S, 2015)
"Cyproheptadine may significantly improve survival outcomes of sorafenib-treated advanced hepatocellular carcinoma patients."3.81Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. ( Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL, 2015)
"Sorafenib has been shown to significantly improve the overall survival of patients with advanced hepatocellular carcinoma (HCC)."3.81Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. ( Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J, 2015)
"While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs."3.81Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. ( Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y, 2015)
"To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed."3.81Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. ( Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K, 2015)
"Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)."3.81Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015)
"Sorafenib is a specific adenosine triphosphate-competitive RAF inhibitor used as a first-line treatment of advanced hepatocellular carcinoma (HCC)."3.81Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. ( Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS, 2015)
"Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits."3.81TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. ( Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J, 2015)
"The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified."3.80Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. ( Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."3.80Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."3.80Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS)."3.80Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N, 2014)
"Sorafenib is a promising drug for advanced hepatocellular carcinoma (HCC); however, treatment may be discontinued for multiple reasons, such as progressive disease, adverse events, or the cost of treatment."3.80Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ, 2014)
"We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC)."3.80Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M, 2014)
"To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma (HCC)."3.80Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M, 2014)
"Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)."3.80Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. ( Kudo, M; Shimada, M; Tanaka, K, 2014)
"Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma."3.80Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. ( Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L, 2014)
"Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)."3.79Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC, 2013)
"Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response."3.79Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. ( Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2013)
"Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC)."3.79In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. ( Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM, 2013)
"To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy."3.79Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. ( Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM, 2013)
"The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC)."3.79Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. ( He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB, 2013)
"Sorafenib, an oral multikinase inhibitor, was approved for the treatment of advanced hepatocellular carcinoma (HCC), but has not been adequately evaluated for safety and effectiveness in Japanese patients with advanced HCC."3.79Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. ( Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013)
"Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART)."3.79Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. ( Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U, 2013)
"To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib."3.79Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2013)
"Sorafenib plasma concentrations were determined by liquid chromatography, every 2 weeks, in consecutive hepatocellular carcinoma patients treated with sorafenib."3.78Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ( Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012)
"To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC)."3.78Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. ( Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W, 2012)
"Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)."3.78Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012)
"Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma."3.78Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. ( De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2012)
"Prospective randomized trials have proven that sorafenib is a valid treatment option for patients with advanced-stage hepatocellular carcinoma (HCC)."3.78Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? ( Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012)
"Sixty-six patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib were enrolled in this retrospective study."3.78Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. ( Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K, 2012)
"This study investigates the effectiveness and safety of sorafenib in a heterogeneous cohort of Child-Pugh A, B and C patients with advanced hepatocellular carcinoma in a clinical-practice scenario."3.78Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. ( Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012)
"To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)."3.78Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. ( Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M, 2012)
" Sorafenib, a novel multi-kinase inhibitor, is approved for the treatment of several human cancers, including advanced hepatocellular carcinoma (HCC)."3.77Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. ( Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X, 2011)
"The purpose of this study was to describe the computed tomography (CT) findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma and to correlate the findings to the overall survival (OS)."3.77Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. ( Choi, JI; Kim, MJ; Lee, JS; Park, JW, 2011)
"Sorafenib is a new drug, multikinase inhibitor, which has been recently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma."3.77Severe sorafenib-induced hand-foot skin reaction. ( Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F, 2011)
"This study compared post-transplant outcomes of patients with hepatocellular carcinoma (HCC) who took sorafenib prior to orthotopic liver transplantation (OLT) with those patients who were not treated with sorafenib."3.77Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE, 2011)
"The purpose of this study was to evaluate the role of des-γ-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC)."3.77Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2011)
"A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC)."3.77Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. ( Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C, 2011)
"The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)."3.77AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011)
"The aim of this study was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC)."3.77Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y, 2011)
"An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)."3.76Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."3.76Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."3.76Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
"To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice."3.76Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010)
"To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment."3.76Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. ( Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2010)
"To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)."3.76[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010)
"This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection."3.75Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009)
" Shortly after chemotherapy with sorafenib [anti-vascular endothelial growth factor (VEGF)] was initiated, progressive renal impairment, hypertension, and nephrotic-range proteinuria developed."3.75Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. ( Jonkers, IJAM; van Buren, M, 2009)
"We investigated the effects of the novel multikinase inhibitor sorafenib, which inhibits tyrosine kinases as well as serine/threonine kinases, in comparison to imatinib, a tyrosine kinase inhibitor, on hemodynamics, pulmonary and right ventricular (RV) remodeling, and downstream signaling in experimental pulmonary hypertension."3.74Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. ( Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N, 2008)
"Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with."2.84Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017)
" Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)."2.82A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). ( Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS, 2016)
"Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity."2.80Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. ( Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK, 2015)
"Sorafenib was given orally at 200 mg BiD for 5 days every week; bevacizumab was administered 5 mg/kg intravenously every 14 days."2.79Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. ( Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J, 2014)
"Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis."2.79Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. ( Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V, 2014)
" Pharmacokinetic sampling was performed during cycle 1."2.78NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
" The most common severe adverse event probably related to sorafenib was diarrhea (12."2.77Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012)
"Most common adverse events (AEs) (grade 3-5) included neutropenia (89%), leucopaenia (81%), hand-foot skin reaction (30%) and fatigue (30%)."2.77Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. ( Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M, 2012)
"Sorafenib 400 mg was administered twice daily continuously starting at day 2 of cycle 1."2.76Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. ( Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."2.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
"Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity."2.75Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. ( Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B, 2010)
"Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies."2.75A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. ( Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E, 2010)
"Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities."2.73Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. ( Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E, 2007)
"Sorafenib 400 mg was administered orally twice daily continuously."2.73A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. ( Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W, 2008)
"Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor."2.73Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. ( Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B, 2008)
" This phase I, open-label, nonrandomized, noncontrolled, single-arm, dose escalation study was done to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, effect on biomarkers, and tumor response with BAY 43-9006 in 19 patients with advanced, refractory solid tumors."2.71Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. ( Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D, 2005)
"Fatigue und hypothyroidism are two common side effects of TKI therapy that can often appear simultaneously."2.53[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. ( Keck, B; Lieb, V; Lüdecke, G; Sikic, D, 2016)
"Sorafenib was the first drug that has shown to increase survival in patients with advanced hepatocelullar carcinoma with an adequate safety profile."2.53Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. ( Bruix, J; Reig, M; Ribeiro de Souza, A, 2016)
"Treatment with sorafenib in patients with progressive DTC and MTC is a promising strategy, but the adverse event rate is high, leading to a high rate of dose reduction or discontinuation."2.50Sorafenib in metastatic thyroid cancer: a systematic review. ( Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L, 2014)
"Sorafenib is a non-selective multiple kinase inhibitor with proven antiproliferative effects in thyroid, renal and hepatocellular carcinoma."2.50Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. ( Haybaeck, J; Petru, E; Smolle, E; Taucher, V, 2014)
"Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death."2.48Hepatocellular carcinoma. ( Bruix, J; Forner, A; Llovet, JM, 2012)
"The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted drugs."2.47Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. ( Takami, HE, 2011)
"Sorafenib is an orally available inhibitor of vascular endothelial growth factor receptors, platelet-derived growth factor receptor-beta, and RAF kinases."2.44Sorafenib in renal cell carcinoma. ( Flaherty, KT, 2007)
"Sorafenib is a potential rescue therapy in patients with TACE failure."1.46Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. ( Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY, 2017)
"Aggravated behaviors of hepatocellular carcinoma (HCC) will occur after inadequate thermal ablation."1.46Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. ( Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD, 2017)
"Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT."1.46Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. ( Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E, 2017)
"Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma."1.46Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. ( Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A, 2017)
"Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes."1.46The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. ( Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C, 2017)
"Sorafenib was discontinued owing to progressing disease for 15 patients and because of serious adverse events (AE) (≥grade 3) for 4 patients, i."1.43Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. ( Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K, 2016)
"Sorafenib treatment could be considered when vandetanib and cabozantinib are not available or after failing these drugs."1.43Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. ( de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR, 2016)
"The purpose of our study was to test the hypothesis that sorafenib-related dermatologic adverse events (AEs) as an early biomarker can predict the long-term outcomes following the combination therapy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S)."1.43Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients. ( Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y, 2016)
"However, its role in hepatocellular carcinoma (HCC) and the underlying mechanisms remain unknown."1.43ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. ( Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX, 2016)
"Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in rats and humans."1.43Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension. ( Chlopicki, S; Fedorowicz, A; Jakubowski, A; Kopec, G; Kutryb-Zając, B; Mateuszuk, Ł; Skórka, T; Słomińska, E; Walczak, M; Zakrzewska, A; Łomnicka, M, 2016)
"Sorafenib was administered orally once the local lesion was under control."1.43[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment]. ( Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T, 2016)
"The aim of the study is to evaluate the relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma (mRCC), with a purpose to guide the judgment of efficacy in sorafenib treatment."1.42The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China. ( Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y, 2015)
"Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity."1.40Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. ( Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK, 2014)
"The management of hepatocellular carcinoma (HCC) in elderly patients is significantly more complicated than in younger patients because of medical comorbidities, advanced status at diagnosis, reduced liver function and altered drug pharmacokinetics."1.39Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. ( Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2013)
"Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity."1.39Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. ( Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA, 2013)
"The purpose of this study is to investigate the effect of exenatide on glycemic control following two administration routes in a streptozotocin/nicotinamide (STZ/NA)-induced diabetic rat model, and to develop a pharmacodynamic model to better understand the disease progression and the action of exenatide in this experimental system."1.39Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. ( Chen, T; Kagan, L; Mager, DE, 2013)
"Sorafenib was approved for advanced HCC based on trials in patients with Child-Pugh class A."1.39Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. ( Byrne, M; Estfan, B; Kim, R, 2013)
"Sorafenib was moderately tolerated, and toxicity reported in 56% of the patients."1.39Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. ( Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J, 2013)
"Sorafenib was able to inhibit the expression of HIF-1α and VEGFA, and sorafenib was able to increase time to recurrence when used as an adjunct to RFA."1.39Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. ( Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL, 2013)
"Sorafenib was well tolerated, with mostly grade 1/2 adverse events and no treatment-related deaths."1.38Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. ( Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P, 2012)
"Here we present a man with pancreatic metastases from PTC, report our experience with sorafenib therapy, and discuss the role of endoscopic ultrasound (EUS)-guided biopsy in its diagnosis."1.38Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012)
"Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known."1.38Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. ( Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R, 2012)
"Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors."1.38Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. ( Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J, 2012)
"• A Markov model simulated disease progression, adverse events and survival with sunitinib vs sorafenib in the US and bevacizumab plus interferon-α (IFN-α) in both countries."1.37Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. ( Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A, 2011)
"Treatment by sorafenib, at the contrary of gemcitabine alone or with oxaliplatine, resulted in a significant reduction in tumor volumes and prolongation of actuarial survival."1.37[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. ( Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D, 2011)
"Sorafenib was given to 83 patients with clear cell mRCC."1.37Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. ( Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2011)
"More than 50% of the worldwide cases of hepatocellular carcinoma occur in China, and this malignancy currently represents the country's second leading cause of cancer death in cities and the leading cause in rural areas."1.37Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. ( Chen, M; Orsini, LS; Qiao, YL; Therneau, T, 2011)
"Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC."1.37Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. ( Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A, 2011)
"Multiple sclerosis is an autoimmune disease of the central nervous system characterized by neuroinflammation and demyelination."1.37Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. ( Crespo, O; Daneman, R; Ho, PP; Kang, SC; Lindstrom, TM; Robinson, WH; Sobel, RA; Steinman, L, 2011)
"Sorafenib was used in 13 and sunitinib in two, including one patient who failed prior sorafenib therapy."1.36Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. ( Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD, 2010)
"Sorafenib-treated rats had significantly less fluorescence leakage as compared with vehicle-treated rats (P < 0."1.36Effect of sorafenib on experimental choroidal neovascularization in the rat. ( Lee, YC; Park, YH; Roh, SY, 2010)
"Treatment continued until disease progression or treatment intolerance occurred."1.36Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. ( Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T, 2010)
"Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal."1.35[Systemic therapy of metastasizing renal cell carcinoma]. ( Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K, 2008)
"In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not received prior systemic therapy, received either oral sorafenib (400 mg twice daily) or placebo until radiological and symptomatic progression."1.35Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. ( Rimassa, L; Santoro, A, 2009)
"Due to the long-lasting course of CLL second cancers can occur in these patients."1.34[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. ( Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P, 2007)
" Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension."1.34Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. ( Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E, 2007)
"However, in chronic renal failure (CRF), serum 1,25(OH)(2)D and Pi levels are often abnormal."1.33Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. ( Eto, N; Miyata, Y; Ohno, H; Yamashita, T, 2005)
"Thirty patients with a metastatic renal cell carcinoma (RCC) already enrolled in a double-blind randomised study were evaluated."1.33To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. ( Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B, 2006)
" Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models."1.32BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. ( Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X, 2004)

Research

Studies (293)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's40 (13.65)29.6817
2010's247 (84.30)24.3611
2020's6 (2.05)2.80

Authors

AuthorsStudies
Kim, H1
Kim, B2
Kim, HS1
Cho, JY3
Zhao, N1
Xia, J1
Xu, B1
Faivre, A1
Katsyuba, E1
Verissimo, T1
Lindenmeyer, M1
Rajaram, RD1
Naesens, M1
Heckenmeyer, C1
Mottis, A1
Feraille, E1
Cippà, P1
Cohen, C1
Longchamp, A1
Allagnat, F1
Rutkowski, JM1
Legouis, D1
Auwerx, J1
de Seigneux, S1
Yeom, DH1
Lee, YS1
Ryu, I1
Lee, S3
Sung, B1
Lee, HB1
Kim, D1
Ahn, JH2
Ha, E1
Choi, YS1
Lee, SH2
You, WK1
Kumakura, S1
Sato, E1
Sekimoto, A1
Hashizume, Y1
Yamakage, S1
Miyazaki, M1
Ito, S1
Harigae, H1
Takahashi, N1
Morevati, M1
Egstrand, S1
Nordholm, A1
Mace, ML1
Andersen, CB1
Salmani, R1
Olgaard, K1
Lewin, E1
Kang, JH1
Kim, DY1
Ahn, SH1
Park, JY2
Kim, BK1
Kim, SU1
Han, KH3
Chou, WC1
Lee, CL1
Yang, TS1
Huang, CY1
Teng, W1
Tseng, YT1
Chen, JS1
Lin, YC1
Hou, MM1
Chang, HH1
Chia-Hsun Hsieh, J1
Huo, Q1
Ge, C1
Tian, H1
Sun, J1
Cui, M1
Li, H2
Zhao, F1
Chen, T2
Xie, H1
Cui, Y1
Yao, M1
Li, J6
Cho, Y1
Lee, JH5
Lee, DH4
Cho, EJ2
Yu, SJ2
Yi, NJ1
Lee, KW1
Kim, YJ2
Yoon, JH3
Suh, KS1
Solms, A1
Reinecke, I1
Fiala-Buskies, S1
Keunecke, A1
Drenth, HJ1
Bruix, J8
Meinhardt, G3
Cleton, A1
Ploeger, B1
Ganten, TM1
Stauber, RE1
Schott, E1
Malfertheiner, P1
Buder, R1
Galle, PR5
Göhler, T1
Walther, M1
Koschny, R1
Gerken, G2
Zhang, R2
Ma, M2
Dong, G1
Yao, RR1
Li, JH1
Zheng, QD1
Dong, YY1
Ma, H3
Gao, DM2
Cui, JF2
Ren, ZG3
Chen, RX2
Tseng, JC1
Narayanan, N1
Ho, G1
Groves, K1
Delaney, J1
Bao, B1
Zhang, J3
Morin, J1
Kossodo, S1
Rajopadhye, M1
Peterson, JD1
Arenberger, P1
Arenbergerova, M1
Shao, YY1
Chen, BB1
Ou, DL1
Lin, ZZ1
Hsu, CH1
Wang, MJ1
Cheng, AL1
Hsu, C1
Wang, P1
Tan, G1
Zhu, M1
Li, W1
Zhai, B1
Sun, X1
Felicetti, F1
Nervo, A1
Piovesan, A1
Berardelli, R1
Marchisio, F1
Gallo, M1
Arvat, E1
Metzelder, SK1
Schroeder, T1
Lübbert, M1
Ditschkowski, M1
Götze, K1
Scholl, S1
Meyer, RG1
Dreger, P1
Basara, N1
Fey, MF1
Salih, HR1
Finck, A1
Pabst, T1
Giagounidis, A2
Kobbe, G1
Wollmer, E1
Finke, J1
Neubauer, A2
Burchert, A2
Nada, Y1
Rashad, N1
Eissa, M1
Ghonaim, A1
Farag, K1
Saadawi, I1
Sheha, A1
El Gewaity, M1
Abdel-Rahman, O1
Peng, Z1
Chen, S2
Wei, M1
Lin, M1
Jiang, C1
Mei, J1
Li, B1
Wang, Y5
Xie, X1
Chen, M2
Qian, G1
Kuang, M1
Suzuki, E5
Kaneko, S3
Okusaka, T3
Ikeda, M2
Yamaguchi, K1
Sugimoto, R1
Aramaki, T1
Asagi, A1
Yasui, K1
Sano, K1
Hosokawa, A1
Kato, N1
Ishii, H1
Sato, T1
Furuse, J5
Meyer, T1
Kim, HY1
Cho, YY1
Kuzuya, T2
Ishigami, M1
Ishizu, Y1
Honda, T1
Hayashi, K1
Ishikawa, T1
Nakano, I1
Hirooka, Y1
Goto, H1
Cai, W1
Yuan, YC1
Li, MY1
Kong, W1
Dong, BJ1
Chen, YH1
Xue, W1
Huang, YR1
Zhou, LX1
Huang, JW3
Zhu, H1
Ma, X1
Zhao, Y6
Duo, J1
Sato, Y1
Nishiofuku, H1
Yasumoto, T1
Nakatsuka, A1
Matsuo, K1
Kodama, Y1
Okubo, H1
Abo, D1
Takaki, H1
Inaba, Y1
Yamakado, K1
Schmidt, TM1
Liu, LI1
Abraham, IE1
Uy, AB1
Dudek, AZ1
Li, L2
Zhao, W2
Wang, M2
Hu, J1
Wang, E1
Liu, L3
Lin, XH1
Liu, HH1
Chen, J2
de la Rubia, JE1
Drehmer, E1
Platero, JL1
Benlloch, M1
Caplliure-Llopis, J1
Villaron-Casales, C1
de Bernardo, N1
AlarcÓn, J1
Fuente, C1
Carrera, S1
Sancho, D1
GarcÍa-Pardo, P1
Pascual, R1
JuÁrez, M1
Cuerda-Ballester, M1
Forner, A4
Sancho-Castillo, S1
Barrios, C1
Obrador, E1
Marchio, P1
Salvador, R1
Holmes, HE1
Dellinger, RW1
Guarente, L1
Estrela, JM1
Eckert, MA1
Coscia, F1
Chryplewicz, A1
Chang, JW1
Hernandez, KM1
Pan, S1
Tienda, SM1
Nahotko, DA1
Li, G2
Blaženović, I1
Lastra, RR1
Curtis, M1
Yamada, SD1
Perets, R1
McGregor, SM1
Andrade, J1
Fiehn, O1
Moellering, RE1
Mann, M1
Lengyel, E1
Santidrian, AF1
Matsuno-Yagi, A1
Ritland, M1
Seo, BB1
LeBoeuf, SE1
Gay, LJ1
Yagi, T1
Felding-Habermann, B1
Montella, L4
Addeo, R4
Cennamo, G2
Vincenzi, B4
Palmieri, R1
Sperlongano, P1
Sperlongano, R1
Iodice, P1
Russo, P1
Del Prete, S3
Maitland, ML1
Wu, K1
Sharma, MR1
Jin, Y1
Kang, SP1
Stadler, WM2
Karrison, TG1
Ratain, MJ1
Bies, RR1
Schwartzberg, LS1
Tauer, KW1
Hermann, RC1
Makari-Judson, G1
Isaacs, C1
Beck, JT1
Kaklamani, V1
Stepanski, EJ1
Rugo, HS1
Wang, W4
Bell-McGuinn, K1
Kirshner, JJ1
Eisenberg, P1
Emanuelson, R1
Keaton, M1
Levine, E1
Medgyesy, DC1
Qamar, R1
Starr, A1
Ro, SK1
Lokker, NA1
Hudis, CA1
Azad, N1
Yu, M1
Davidson, B1
Choyke, P1
Chen, CC1
Wood, BJ1
Venkatesan, A1
Henning, R1
Calvo, K1
Minasian, L1
Edelman, DC1
Meltzer, P1
Steinberg, SM1
Annunziata, CM1
Kohn, EC1
Pawaskar, DK1
Straubinger, RM1
Fetterly, GJ1
Hylander, BH1
Repasky, EA1
Ma, WW1
Jusko, WJ1
Chan, JA1
Mayer, RJ1
Jackson, N1
Malinowski, P1
Regan, E1
Kulke, MH1
Levy, A1
Menard, J1
Albiges, L1
Loriot, Y1
Di Palma, M1
Fizazi, K1
Escudier, B6
Sposito, C2
Mariani, L1
Germini, A2
Flores Reyes, M1
Bongini, M2
Grossi, G1
Bhoori, S2
Mazzaferro, V5
Bruno, R1
Mercier, F1
Claret, L1
Chevreau, C2
Le Cesne, A1
Ray-Coquard, I1
Italiano, A2
Cioffi, A1
Isambert, N1
Robin, YM1
Fournier, C1
Clisant, S1
Chaigneau, L1
Bay, JO1
Bompas, E1
Gauthier, E1
Blay, JY2
Penel, N1
Paik, YH2
Lim, HY5
Kim, YG1
Lim, HK1
Min, YW1
Gwak, GY2
Choi, MS2
Koh, KC2
Paik, SW2
Yoo, BC2
Wang, Z3
Wu, XL1
Zeng, WZ1
Xu, GS1
Xu, H1
Weng, M1
Hou, JN1
Jiang, MD1
Kurzrock, R1
Atkins, J1
Wheler, J1
Fu, S3
Naing, A1
Busaidy, N1
Hong, D1
Sherman, S1
Zhao, RN1
Nie, LH1
Gong, R1
Wang, JZ1
Wazir, R1
Liu, LR1
Song, TR1
Wei, Q1
Reig, M3
Rimola, J1
Torres, F1
Darnell, A1
Rodriguez-Lope, C1
Llarch, N1
Ríos, J1
Ayuso, C1
Mitsunaga, S1
Shimizu, S1
Ohno, I1
Takahashi, H1
Okuyama, H1
Kuwahara, A1
Kondo, S1
Morizane, C1
Ueno, H1
Satake, M1
Arai, Y1
Zocco, MA1
Garcovich, M1
Lupascu, A1
Di Stasio, E1
Roccarina, D1
Annicchiarico, BE1
Riccardi, L1
Ainora, ME1
Ponziani, F1
Caracciolo, G1
Rapaccini, GL1
Landolfi, R1
Siciliano, M1
Pompili, M1
Gasbarrini, A2
Papachristou, I1
Giatras, N1
Ussher, M1
Shingina, A1
Hashim, AM1
Haque, M1
Suen, M1
Yoshida, EM1
Gill, S1
Donnellan, F1
Weiss, AA1
Choi, GH2
Shim, JH3
Kim, MJ2
Ryu, MH3
Ryoo, BY3
Kang, YK4
Shin, YM1
Kim, KM2
Lim, YS2
Lee, HC4
Kagan, L1
Mager, DE1
Zustovich, F1
Landi, L1
Lombardi, G1
Porta, C3
Galli, L1
Fontana, A1
Amoroso, D1
Galli, C1
Andreuccetti, M1
Falcone, A1
Zagonel, V1
Yoon, EL1
Yeon, JE1
Lee, HJ1
Suh, SJ1
Lee, SJ1
Kang, SH1
Kang, K1
Yoo, YJ1
Kim, JH2
Yim, HJ2
Byun, KS1
Li, Y3
Zheng, YB1
Liu, B2
Hu, BS2
He, X3
Lu, LG2
Guerin, M1
Salem, N1
Walz, J1
Dermeche, S1
Gravis, G1
Hutson, TE2
Esteban, E1
Bjarnason, GA1
Pittman, KB1
Senico, P1
Niethammer, A1
Lu, DR1
Hariharan, S2
Motzer, RJ1
Poprach, A2
Pavlik, T2
Melichar, B2
Kubackova, K1
Bortlicek, Z2
Svoboda, M1
Lakomy, R1
Vyzula, R2
Kiss, I1
Dusek, L1
Buchler, T2
Thomson, DJ1
Silva, P1
Denton, K1
Bonington, S1
Mak, SK1
Swindell, R1
Homer, J1
Sykes, AJ1
Lee, LW1
Yap, BK1
Slevin, NJ1
Samalin, E1
Bouché, O1
Thézenas, S1
Francois, E1
Adenis, A1
Bennouna, J2
Taieb, J1
Desseigne, F1
Seitz, JF2
Conroy, T1
Galais, MP1
Assenat, E2
Crapez, E1
Poujol, S1
Bibeau, F1
Boissière, F1
Laurent-Puig, P1
Ychou, M1
Mazard, T1
Lee, JE1
Bae, SH2
Choi, JY1
Yoon, SK2
You, YK1
Lee, MA1
Arizumi, T2
Ueshima, K2
Takeda, H1
Osaki, Y1
Takita, M2
Inoue, T2
Kitai, S2
Yada, N2
Hagiwara, S2
Minami, Y2
Sakurai, T2
Nishida, N1
Kudo, M8
Thomas, L1
Lai, SY1
Dong, W1
Feng, L2
Dadu, R2
Regone, RM1
Cabanillas, ME3
Chow, PK2
Poon, DY1
Khin, MW1
Singh, H1
Han, HS1
Goh, AS1
Choo, SP1
Lai, HK1
Lo, RH1
Tay, KH1
Lim, TG1
Gandhi, M1
Tan, SB1
Soo, KC2
Chen, H3
Cai, G1
Qi, X1
Han, G2
Smolle, E1
Taucher, V1
Petru, E1
Haybaeck, J1
Rexer, H2
Waguespack, SG2
Sherman, SI2
Hu, MI1
Busaidy, NL2
Jimenez, C1
Habra, MA1
Ying, AK1
Bassett, RL1
Imedio, ER1
Beveridge, RD1
Urtasun, JA1
Campos, GB1
Estellés, DL1
Esparcia, MF1
Daroqui, JC1
Huerta, ÁS1
Ortiz, AG1
Salcedo, JM1
Akutsu, N1
Sasaki, S1
Takagi, H1
Motoya, M1
Shitani, M1
Igarashi, M1
Hirayama, D1
Wakasugi, H1
Yamamoto, H1
Kaneto, H1
Yonezawa, K1
Yawata, A1
Adachi, T1
Hamamoto, Y1
Shinomura, Y1
Miyahara, K1
Nouso, K1
Yamamoto, K1
Fu, SR1
Zhang, YQ1
Zhan, MX1
Li, JP1
Mahalingam, D1
Malik, L1
Beeram, M1
Rodon, J1
Sankhala, K1
Mita, A1
Benjamin, D1
Ketchum, N1
Michalek, J1
Tolcher, A1
Wright, J2
Sarantopoulos, J1
Llovet, JM6
Zhang, L4
Hu, P1
Chen, X1
Bie, P1
Sounni, NE1
Cimino, J1
Blacher, S1
Primac, I1
Truong, A1
Mazzucchelli, G1
Paye, A1
Calligaris, D1
Debois, D1
De Tullio, P1
Mari, B1
De Pauw, E1
Noel, A1
Song, DS1
Song, MJ1
Chung, WJ1
Jang, JY1
Kim, YS1
Cho, SB1
Park, SY2
Yang, JM1
Zhu, AX1
Cattan, S1
Poon, RT3
Blanc, JF2
Vogel, A1
Chen, CL1
Dorval, E1
Peck-Radosavljevic, M3
Santoro, A9
Daniele, B2
Jappe, A1
Perraud, K1
Anak, O1
Sellami, DB1
Chen, LT1
Yang, M1
Yuan, JQ1
Bai, M1
Han, GH2
Ogasawara, S4
Chiba, T4
Ooka, Y4
Kanogawa, N3
Motoyama, T3
Tawada, A4
Kanai, F3
Yoshikawa, M1
Yokosuka, O4
Yada, M1
Masumoto, A1
Motomura, K1
Tajiri, H1
Morita, Y1
Suzuki, H1
Senju, T1
Koyanagi, T1
Han, S1
Marotta, V1
Di Somma, C1
Rubino, M1
Sciammarella, C1
Modica, R1
Camera, L1
Del Prete, M1
Marciello, F1
Ramundo, V1
Circelli, L1
Buonomano, P1
Colao, A1
Faggiano, A1
Bolondi, L5
Craxi, A2
Trevisani, F2
Di Costanzo, GG2
Fagiuoli, S1
Cammà, C2
Bruzzi, P1
Danesi, R1
Spandonaro, F1
Boni, C1
Colombo, M2
Tanaka, K4
Shimada, M1
Simmons, K1
Michels, AW1
Peng, S1
Xu, F1
Jia, C1
Xu, Y2
Dai, C1
Vilgrain, V1
Abdel-Rehim, M1
Sibert, A1
Ronot, M1
Lebtahi, R1
Castéra, L1
Chatellier, G1
Lara, PN1
Moon, J1
Redman, MW1
Semrad, TJ1
Kelly, K1
Allen, JW1
Gitlitz, BJ1
Mack, PC1
Gandara, DR1
Grignani, G1
Palmerini, E1
Ferraresi, V1
D'Ambrosio, L1
Bertulli, R1
Asaftei, SD1
Tamburini, A1
Pignochino, Y1
Sangiolo, D1
Marchesi, E1
Capozzi, F1
Biagini, R1
Gambarotti, M1
Fagioli, F1
Casali, PG1
Picci, P1
Ferrari, S1
Aglietta, M1
Sohn, W1
Ahn, JM1
Sinn, DH1
Hollebecque, A1
Malka, D1
Ferté, C1
Ducreux, M1
Boige, V1
Turnes, J1
Díaz, R1
Hernandez-Guerra, M1
Gómez, M1
Castells, L1
Bustamante, J2
Espinosa, MD1
Fernández-Castroagudín, J1
Serrano, T1
Rendón, P1
Andrade, R1
Salgado, M1
Arenas, J1
Vergara, M1
Sala, M1
Polo, BA1
Granizo, IM1
Gonzálvez, ML1
Viudez, A1
Lim, S1
Han, J1
Kim, GM1
Choi, HJ1
Feng, YM1
Feng, CW1
Lu, CL1
Lee, MY1
Chen, CY1
Chen, SC1
Araki, H1
Tsuzuki, T1
Kimura, T1
Yamada, S2
Sassa, N1
Yoshino, Y1
Hattori, R1
Gotoh, M1
Han, T1
Xiang, DM1
Sun, W1
Liu, N2
Sun, HL1
Wen, W1
Shen, WF1
Wang, RY1
Chen, C3
Wang, X1
Cheng, Z1
Li, HY1
Wu, MC1
Cong, WM1
Feng, GS1
Ding, J2
Wang, HY2
Zhang, P2
Yang, Y2
Wen, F2
Tang, R1
Du, Z1
Zhou, J2
Li, Q2
Petrou, P1
Fukubayashi, K1
Tanaka, M4
Izumi, K1
Watanabe, T1
Fujie, S1
Kawasaki, T1
Yoshimaru, Y1
Tateyama, M1
Setoyama, H1
Naoe, H1
Kikuchi, K1
Sasaki, Y1
Lim, Y1
Gondek, L1
Wang, Q2
Chang, E1
Huso, DL1
Foerster, S1
Marchionni, L1
McGovern, K1
Watkins, DN1
Peacock, CD1
Levis, M1
Smith, BD1
Merchant, AA1
Small, D1
Matsui, W1
Zhang, Y2
Fan, W1
Zhu, K1
Lu, L2
Huang, J1
Yang, J2
Huang, Y1
Yao, W1
Aedo, V1
Cristina, V1
Raymond, E1
Faivre, S2
Wang, L1
Cong, N1
Shi, C1
Bu, W1
Song, J1
Gazzola, A1
Di Donato, R1
Omae, K1
Kondo, T1
Kennoki, T1
Takagi, T1
Iizuka, J1
Kobayashi, H1
Hashimoto, Y1
Tanabe, K1
Leconte, M1
Santulli, P1
Chouzenoux, S1
Marcellin, L1
Cerles, O1
Chapron, C1
Dousset, B1
Batteux, F1
Guan, DX1
Shi, J1
Zhao, JS1
Long, LY1
Chen, TW1
Zhang, EB1
Feng, YY1
Bao, WD1
Deng, YZ1
Qiu, L1
Zhang, XL1
Koeffler, HP1
Cheng, SQ1
Li, JJ1
Xie, D1
Liu, JY1
Chiang, T1
Liu, CH1
Chern, GG1
Lin, TT1
Gao, DY1
Chen, Y3
Ho, V1
Lim, TS1
Lee, J2
Steinberg, J1
Szmyd, R1
Tham, M1
Yaligar, J1
Kaldis, P1
Abastado, JP1
Chew, V1
Djokovic, D1
Trindade, A1
Gigante, J1
Pinho, M1
Harris, AL1
Duarte, A1
Furman, BL1
Takayama, T3
Chau, GY1
Cai, J1
Tak, WY2
Song, T1
Roayaie, S1
Lee, KS1
Makuuchi, M1
Souza, F1
Berre, MA1
Devapatla, B1
Sharma, A1
Woo, S1
Kanda, M1
Sugimoto, H1
Kodera, Y1
Saito, T2
Cao, G1
Li, X2
Qin, C1
Röllig, C1
Serve, H1
Hüttmann, A1
Noppeney, R1
Müller-Tidow, C1
Krug, U1
Baldus, CD1
Brandts, CH1
Kunzmann, V1
Einsele, H1
Krämer, A1
Schäfer-Eckart, K1
Krause, SW1
Mackensen, A1
Aulitzky, W1
Herbst, R1
Hänel, M1
Kiani, A1
Frickhofen, N1
Kullmer, J1
Kaiser, U1
Link, H1
Geer, T1
Reichle, A1
Junghanß, C1
Repp, R1
Heits, F1
Dürk, H1
Hase, J1
Klut, IM1
Illmer, T1
Bornhäuser, M1
Schaich, M1
Parmentier, S1
Görner, M1
Thiede, C1
von Bonin, M1
Schetelig, J1
Kramer, M1
Berdel, WE1
Ehninger, G1
Ivanyi, P1
Grünwald, V2
Ganghammer, S1
Gutjahr, J1
Hutterer, E1
Krenn, PW1
Pucher, S1
Zelle-Rieser, C1
Jöhrer, K1
Wijtmans, M1
Leurs, R1
Smit, MJ1
Gattei, V1
Greil, R1
Hartmann, TN1
Zheng, Y1
Wang, F1
Wu, G1
Chen, P1
Lu, J1
Li, P1
Wang, J1
Lu, X1
Yuan, J1
Tovar, V1
Cornella, H1
Moeini, A1
Vidal, S1
Hoshida, Y1
Sia, D1
Peix, J1
Cabellos, L1
Alsinet, C1
Torrecilla, S1
Martinez-Quetglas, I1
Lozano, JJ1
Desbois-Mouthon, C1
Solé, M1
Domingo-Domenech, J1
Villanueva, A2
Koo, DH1
Park, I1
You, D1
Jeong, IG1
Song, C1
Hong, B1
Hong, JH1
Ahn, H1
Lee, JL1
de Castroneves, LA1
Negrão, MV1
de Freitas, RM1
Papadia, C1
Lima, JV1
Fukushima, JT1
Simão, EF1
Kulcsar, MA1
Tavares, MR1
Jorge, AA1
de Castro, G1
Hoff, PM1
Hoff, AO1
Itokawa, N1
Atsukawa, M1
Tsubota, A1
Okubo, T1
Arai, T1
Nakagawa, A1
Kondo, C1
Iwakiri, K1
Ponziani, FR1
Flores, M1
Facciorusso, A1
Geschwind, JF1
Marrero, JA2
Venook, AP1
Chen, XP1
Bronowicki, JP1
Dagher, L1
Ladrón de Guevara, L1
Papandreou, C1
Sanyal, AJ1
Ye, SL2
Nakajima, K1
Lehr, R1
Heldner, S1
Lencioni, R1
Wada, Y1
Takami, Y1
Tateishi, M1
Ryu, T1
Mikagi, K1
Saitsu, H1
Shirota, N1
Saito, K1
Sugimoto, K1
Takara, K1
Moriyasu, F1
Tokuuye, K1
Lim, SM1
Cho, BC1
Kim, SW1
Kang, SY1
Heo, DS1
Kim, HT1
Kim, DW1
Jung, M1
Choi, JH1
Shim, HS1
Choi, JR1
Zhou, SL1
Zhou, ZJ1
Hu, ZQ1
Huang, XW1
Chen, EB1
Fan, J1
Cao, Y2
Dai, Z1
Ikeda, K1
Matsuzaki, Y1
Minami, H1
Okayama, Y1
Sunaya, T1
Ito, Y1
Inuyama, L1
Okita, K2
Shi, L1
Lin, H1
Jin, RA1
Xu, J1
Sun, Y2
Ma, WL2
Yeh, S2
Cai, X1
Chang, C2
Bai, W2
Liu, J2
Lv, W1
Sahu, S1
Guan, S1
Qin, X1
Ren, W1
Mu, W1
Guo, W2
Gu, S1
Ma, Y1
Yin, Z1
Duran, R1
Fan, D1
Zhang, Z1
Garuti, F1
Camelli, V1
Spinardi, L1
Bucci, L1
Hou, Y1
Cai, XB1
Wheeler, J1
Fu, P1
Sikic, D1
Lüdecke, G1
Lieb, V1
Keck, B1
Wu, FQ1
Fang, T1
Yu, LX1
Lv, GS1
Lv, HW1
Liang, D1
Li, T1
Wang, CZ1
Tan, YX1
Tang, L2
Guo, LN1
Tang, SH1
Yang, W1
Leung, HW1
Liu, CF1
Chan, AL1
Zeng, J1
Lv, L1
Mei, ZC1
Kaibori, M1
Sakai, K1
Ishizaki, M1
Matsushima, H1
De Velasco, MA1
Matsui, K1
Iida, H1
Kitade, H1
Kwon, AH1
Nagano, H1
Wada, H1
Haji, S1
Tsukamoto, T1
Kanazawa, A1
Takeda, Y1
Takemura, S1
Kubo, S1
Nishio, K1
Nakano, M2
Kuromatsu, R2
Nagamatsu, H2
Satani, M2
Niizeki, T2
Okamura, S1
Iwamoto, H2
Shimose, S1
Shirono, T1
Noda, Y1
Koga, H2
Torimura, T2
Inoue, M1
Wakamatsu, T1
Brizzi, MP1
Pignataro, D1
Tampellini, M1
Scagliotti, GV1
Di Maio, M1
Fedorowicz, A1
Mateuszuk, Ł1
Kopec, G1
Skórka, T1
Kutryb-Zając, B1
Zakrzewska, A1
Walczak, M1
Jakubowski, A1
Łomnicka, M1
Słomińska, E1
Chlopicki, S1
Ribeiro de Souza, A1
Brower, V1
Ziogas, DC1
Papadatos-Pastos, D1
Thillai, K1
Korantzis, I1
Chowdhury, R1
Suddle, A1
O'Grady, J1
Al-Khadimi, G1
Allen, N1
Heaton, N1
Ross, PJ1
Sarker, D1
Cai, Z1
Wang, C1
Liu, P1
Shen, P1
Han, Y1
Bouattour, M1
Soubrane, O1
de Gramont, A1
Liang, C1
Liu, Z1
Zhu, Y2
Wu, Z1
Galmiche, A1
Stadler, N1
Wendum, D1
Segal-Bendirdjian, E1
Paradis, V1
Forgez, P1
Wendel, C1
Campitiello, M1
Plastino, F1
Eid, N1
Hennequin, L1
Quétin, P1
Longo, R1
Eritja, N1
Chen, BJ1
Rodríguez-Barrueco, R1
Santacana, M1
Gatius, S1
Vidal, A1
Martí, MD1
Ponce, J1
Bergadà, L1
Yeramian, A1
Encinas, M1
Ribera, J1
Reventós, J1
Boyd, J1
Matias-Guiu, X1
Dolcet, X1
Llobet-Navàs, D1
Pinato, DJ1
Yen, C1
Bettinger, D1
Ramaswami, R1
Ward, C1
Pirisi, M1
Burlone, ME1
Thimme, R1
Sharma, R1
Yoshikawa, T1
Nomi, T1
Hokuto, D1
Yamato, I1
Yasuda, S1
Obara, S1
Kawaguchi, C1
Kinoshita, S1
Nishiwada, S1
Nagai, M1
Akahori, T1
Yamada, T1
Sho, M1
Kanehiro, H1
Nakajima, Y1
Dutta, R1
Mahato, RI1
Kawaoka, T2
Aikata, H2
Teraoka, Y1
Inagaki, Y1
Honda, F1
Hatooka, M1
Morio, K1
Morio, R1
Kobayashi, T2
Nagaoki, Y2
Nakahara, T2
Hiramatsu, A2
Tsuge, M1
Imamura, M1
Kawakami, Y1
Chayama, K2
Cho, HJ1
Kim, SS1
Nam, JS1
Oh, MJ1
Kang, DR1
Kim, JK1
Yang, MJ1
Hwang, JC1
Lim, SG1
Shin, SJ1
Lee, KM1
Yoo, BM1
Lee, KJ1
Cho, SW1
Cheong, JY1
Stemmler, HJ1
Heinemann, V1
Vom Dorp, F1
Börgermann, C1
Rose, A1
Becker, M1
Rübben, H1
Merseburger, AS1
Kuczyk, MA1
Ricci, S1
Hilgard, P1
Gane, E1
de Oliveira, AC1
Raoul, JL2
Schwartz, M1
Zeuzem, S1
Greten, TF2
Borbath, I1
Häussinger, D1
Giannaris, T1
Shan, M4
Moscovici, M2
Voliotis, D2
Staehler, M1
Haseke, N1
Zilinberg, K1
Stadler, T1
Karl, A1
Stief, CG1
Park, JW2
Choi, JI2
Park, BJ1
Kim, CM1
Klein, M1
Schermuly, RT1
Ellinghaus, P1
Milting, H1
Riedl, B2
Nikolova, S1
Pullamsetti, SS1
Weissmann, N1
Dony, E1
Savai, R1
Ghofrani, HA1
Grimminger, F1
Busch, AE1
Schäfer, S1
Copur, MS1
Diaz-Cano, SJ1
Huynh, H1
Lee, JW1
Ngo, VC1
Lew, GB1
Lam, IW1
Ong, HS1
Chung, A1
Zimmermann, K2
Schmittel, A1
Steiner, U1
Asemissen, AM1
Knoedler, M1
Thiel, E1
Miller, K4
Keilholz, U4
Komuro, A1
Yashiro, M1
Iwata, C1
Morishita, Y1
Johansson, E1
Matsumoto, Y1
Watanabe, A1
Aburatani, H1
Miyoshi, H1
Kiyono, K1
Shirai, YT1
Suzuki, HI1
Hirakawa, K1
Kano, MR1
Miyazono, K1
Jonkers, IJAM1
van Buren, M1
Rimassa, L3
Mendizabal, M1
Reddy, KR1
Zołnierek, J1
Nurzyński, P1
Langiewicz, P1
Oborska, S1
Waśko-Grabowska, A1
Kuszatal, E1
Obrocka, B1
Szczylik, C2
Jilaveanu, LB1
Zito, CR1
Aziz, SA1
Conrad, PJ1
Schmitz, JC1
Sznol, M1
Camp, RL1
Rimm, DL1
Kluger, HM1
La Vine, DB1
Coleman, TA1
Davis, CH1
Carbonell, CE1
Davis, WB1
Lammer, J1
Rosmorduc, O1
Sangro, B2
Smith, AD2
Lieber, ML2
Shah, SN2
Prete, SD1
Caraglia, M3
Maiorino, L1
Montesarchio, V1
Piai, G1
Febbraro, A1
Tarantino, L1
Capasso, E1
Palmieri, G1
Guarrasi, R1
Bianco, M1
Mamone, R1
Savastano, C1
Pisano, A1
Sabia, A1
D'Agostino, A1
Faiola, V1
Santini, D2
Russo, A1
Giuliani, F1
Rizzo, S1
Venditti, O1
Frezza, AM1
Colucci, G1
Tonini, G2
Gschwend, JE1
Verset, G1
Maréchal, R1
Bali, MA1
Devière, J1
Van Laethem, JL1
Bronstein, Y1
Williams, MD1
Hernandez, M1
Lopez, A1
Balsom, SM1
Trolli, E1
Rose, J1
Bloomston, M1
Patel, T1
Bekaii-Saab, TS1
Bergmann, L2
Albers, P1
Gschwend, J2
Jäger, E1
Rini, BI1
Remer, EM1
Yoon, DH1
Lee, SG1
Hwang, S1
Suh, DJ2
Kim, TW1
Ahn, CS1
Kim, KH1
Moon, DB1
Park, YH1
Roh, SY1
Lee, YC1
Connock, M1
Round, J1
Bayliss, S1
Tubeuf, S1
Greenheld, W1
Moore, D1
Coriat, R3
Ropert, S4
Mir, O3
Billemont, B1
Chaussade, S2
Massault, PP1
Blanchet, B3
Vignaux, O2
Goldwasser, F3
Ueda, T2
Imamura, Y1
Komaru, A1
Fukasawa, S1
Sazuka, T1
Suyama, T1
Naya, Y1
Nihei, N1
Ichikawa, T1
Maruoka, M1
Peña, C1
Lathia, C3
Bukowski, RM3
Bono, AV1
Pannellini, T1
Liberatore, M1
Montironi, R1
Cunico, SC1
Cheng, L1
Sasso, F1
Musiani, P1
Iezzi, M1
Yau, T1
Pang, R1
Chan, P1
Tomita, Y1
Rowe, IA1
Brendel, E2
Ludwig, M1
Robert, C1
Soria, JC1
Armand, JP1
Larkin, JM1
Ferguson, TR1
Pickering, LM1
Edmonds, K1
James, MG1
Thomas, K1
Banerji, U1
Berns, B1
de Boer, C1
Gore, ME2
Wörns, MA2
Schuchmann, M2
Düber, C1
Otto, G1
Weinmann, A2
Abou-Alfa, GK1
Johnson, P1
Knox, JJ1
Capanu, M1
Davidenko, I1
Lacava, J1
Leung, T1
Gansukh, B1
Saltz, LB1
Xu, LT1
Chen, Z1
Lin, JH1
Zhou, ZH1
Meng, ZQ1
Liu, LM1
Gan, YH1
Wang, YH1
Zhang, BH1
Xie, XY2
Ge, NL1
Chen, L1
Shen, Y1
Luo, Q1
Yu, Y1
Lu, H1
Zhu, R1
Benedict, A1
Figlin, RA1
Sandström, P1
Harmenberg, U1
Ullén, A1
Charbonneau, C1
Sandin, R1
Remák, E1
Négrier, S2
Kontovinis, L1
Laschos, K1
Karadimou, A1
Andreadis, C1
Bamias, A1
Paraskevopoulos, P1
Dimopoulos, M1
Papazisis, K1
Cao, M1
Youn, JI1
Cabrera, R1
Zhang, X2
Gabrilovich, D1
Nelson, DR1
Liu, C1
Gouya, H1
Sogni, P1
Pol, S1
Legmann, P1
Pazo Cid, RA1
Lao, J1
Lanzuela, M1
Bisaga, GN1
Odinak, MM1
Boĭko, AN1
Mel'nik, IuB1
Popova, NF1
Lee, JS1
Akladios, CY1
Bour, G1
Balboni, G1
Mutter, D1
Marescaux, J1
Aprahamian, M1
Takami, HE1
Kusuda, Y1
Miyake, H1
Behnsawy, HM1
Fukuhara, T1
Inoue, TA1
Fujisawa, M1
Herrmann, E1
Marschner, N1
Grimm, MO1
Ohlmann, CH1
Hutzschenreuter, U1
Overkamp, F1
Groschek, M1
Blumenstengel, K1
Pühse, G1
Steiner, T1
Zhang, HL1
Wang, CF1
Yao, XD1
Zhang, SL1
Dai, B1
Shen, YJ1
Zhu, YP1
Shi, GH1
Ye, DW1
Lee, KB1
Lee, MJ1
Bae, SC1
Jang, JJ1
Weikert, S1
Kempkensteffen, C1
Busch, J1
Johannsen, M1
Flörcken, A1
Westermann, J1
Weinkauf, L1
Siebels, M2
Hegele, A1
Varga, Z1
Oberneder, R1
Doehn, C1
Heinzer, H1
Therneau, T1
Orsini, LS1
Qiao, YL1
Abbadessa, G1
Pressiani, T1
Carrillo-Infante, C1
Cucchi, E1
Cuesta, L1
Betlloch, I1
Toledo, F1
Latorre, N1
Monteagudo, A1
Imanaka, K1
Chida, N1
Nakachi, K1
Hori, T1
Kumada, H1
Hayashi, N1
Tsubouchi, H1
Matsui, O1
Wada, M1
Yamaguchi, I1
Ohya, T1
Ahn, HK1
Sun, JM1
Park, SH1
Park, JO1
Park, YS1
Kang, WK1
Truesdale, AE1
Caldwell, SH1
Shah, NL1
Argo, CK1
Al-Osaimi, AM1
Schmitt, TM1
Northup, PG1
Nagai, T1
Tatsumi, C1
Ishikawa, E1
Chung, H1
Crespo, O1
Kang, SC1
Daneman, R1
Lindstrom, TM1
Ho, PP1
Sobel, RA1
Steinman, L1
Robinson, WH1
Iavarone, M1
Cabibbo, G1
Piscaglia, F1
Zavaglia, C1
Grieco, A1
Villa, E1
Gomez-Martin, C1
Castroagudin, JF1
Salcedo, M1
Garralda, E1
Testillano, M1
Herrero, I1
Matilla, A1
Nabors, LB2
Supko, JG2
Rosenfeld, M1
Chamberlain, M1
Phuphanich, S2
Batchelor, T1
Desideri, S1
Ye, X2
Gujar, S1
Grossman, SA2
Gamstätter, T1
Schadmand-Fischer, S1
Spies, PR1
Niederle, IM1
Arrondeau, J1
Boudou-Rouquette, P1
Dumas, G1
Rodrigues, MJ1
Rousseau, B1
Asahina, Y1
Tsuchiya, K1
Suzuki, Y1
Hoshioka, T1
Tamaki, S1
Kato, T1
Yasui, Y1
Hosokawa, T1
Ueda, K1
Nakanishi, H1
Itakura, J1
Takahashi, Y1
Kurosaki, M1
Izumi, N1
Allavena, P1
Mantovani, A1
Awada, A1
Hendlisz, A1
Christensen, O1
Lathia, CD1
Bartholomeus, S1
Lebrun, F1
de Valeriola, D1
Radtke, M1
Delaunoit, T1
Piccart-Gebhart, M1
Gil, T1
Hsu, CL1
Yeh, CC1
Wu, MH1
Huang, CK1
Jeng, LB1
Hung, YC1
Lin, TY1
Sansonno, D1
Lauletta, G1
Russi, S1
Conteduca, V1
Sansonno, L1
Dammacco, F1
Alzahrani, AS1
AlQaraawi, A1
Al Sohaibani, F1
Almanea, H1
Abalkhail, H1
Pinter, M1
Hucke, F1
Graziadei, I1
Vogel, W1
Maieron, A1
Königsberg, R1
Stauber, R1
Grünberger, B1
Müller, C1
Kölblinger, C1
Sieghart, W1
Estfan, B1
Byrne, M1
Kim, R1
Woo, HY1
Heo, J1
Yoon, KT1
Kim, GH1
Kang, DH1
Song, GA1
Cho, M1
Tortora, R1
Iodice, L1
Lanza, AG1
Lampasi, F1
Tartaglione, MT1
Picciotto, FP1
Mattera, S1
De Luca, M1
Sherman, M1
Beaugrand, M1
Sangiovanni, A1
Nadel, A1
Abrahamova, J1
Sacco, R1
Bargellini, I1
Ginanni, B1
Bertini, M1
Faggioni, L1
Federici, G1
Romano, A1
Bertoni, M1
Metrangolo, S1
Altomare, E1
Parisi, G1
Tumino, E1
Scaramuzzino, A1
Bresci, G1
Bartolozzi, C1
Paz-Ares, LG1
Biesma, B1
Heigener, D1
von Pawel, J1
Eisen, T2
Liao, M1
Gans, S1
Syrigos, K1
Le Marie, E1
Gottfried, M1
Vansteenkiste, J1
Alberola, V1
Strauss, UP1
Montegriffo, E1
Ong, TJ1
Murakami, E1
Naeshiro, N1
Honda, Y1
Miyaki, D1
Takaki, S1
Waki, K1
Takahashi, S1
Calvieri, A1
Silletta, M1
Vespasiani, U1
Picardi, A1
Montemurro, M1
Gelderblom, H1
Bitz, U1
Schütte, J1
Joensuu, H1
Trent, J1
Bauer, S1
Rutkowski, P1
Duffaud, F1
Pink, D1
Simonelli, M1
Zucali, PA1
Lorenzi, E1
Rubino, L1
De Vincenzo, F1
De Sanctis, R1
Perrino, M1
Mancini, L1
Di Tommaso, L1
Masci, G1
Zuradelli, M1
Suter, MB1
Bertossi, M1
Fattuzzo, G1
Giordano, L1
Roncalli, MG1
Sakata, K1
Matsugaki, S1
Kajiwara, M1
Fukuizumi, K1
Tajiri, N1
Matsukuma, N1
Sakai, T1
Ono, N1
Yano, Y1
Kurogi, J1
Takata, A1
Sumie, S1
Aino, H1
Sata, M1
Shiozawa, K1
Watanabe, M2
Kikuchi, Y1
Kudo, T1
Maruyama, K1
Sumino, Y1
Xu, M1
Xie, XH1
Xu, ZF1
Liu, GJ1
Zheng, YL1
Huang, GL1
Zheng, SG1
Lü, MD1
Berretta, M1
Di Benedetto, F1
Dal Maso, L1
Cacopardo, B1
Nasti, G1
Facchini, G1
Bearz, A1
Spina, M1
Garlassi, E1
De Re, V1
Fiorica, F1
Lleshi, A1
Tirelli, U1
Larkin, J1
Paine, A1
Tumur, I1
Cappelleri, JC1
Healey, PJ1
Foley, G1
Mitchell, S1
Kroes, M1
Hammond, E1
Brandt, R1
Dredge, K1
Wang, YJ1
Qi, XS1
Yin, ZX1
He, CY1
Li, RJ1
Wu, KC1
Xia, JL1
Fan, DM1
Peereboom, DM1
Ahluwalia, MS1
Hilderbrand, SL1
Rosenfeld, MR1
Mikkelsen, T1
Fendrich, V1
Maschuw, K1
Rehm, J1
Buchholz, M1
Holler, JP1
Slater, EP1
Bartsch, DK1
Waldmann, J1
Maroto, JP1
del Muro, XG1
Mellado, B1
Perez-Gracia, JL1
Andrés, R1
Cruz, J1
Gallardo, E1
Domenech, M1
Arranz, JA1
Meana, JA1
Nakazawa, T1
Hidaka, H1
Takada, J1
Okuwaki, Y1
Tanaka, Y1
Shibuya, A1
Minamino, T1
Kokubu, S1
Koizumi, W1
Wilhelm, S1
Chien, DS1
Couzin, J1
Wilhelm, SM1
Carter, C1
Wilkie, D2
McNabola, A2
Rong, H1
Vincent, P1
McHugh, M1
Shujath, J1
Gawlak, S1
Eveleigh, D1
Rowley, B1
Adnane, L1
Lynch, M1
Auclair, D1
Taylor, I1
Gedrich, R1
Voznesensky, A1
Post, LE1
Bollag, G1
Trail, PA1
Eto, N1
Miyata, Y1
Ohno, H1
Yamashita, T1
Bover, J1
Ortiz-Herbener, F1
Ballarín, J1
Andrés, E1
Barceló, P1
Clark, JW1
Eder, JP1
Ryan, D1
Lenz, HJ1
Lamuraglia, M1
Chami, L1
Schwartz, B3
Leclère, J1
Roche, A1
Lassau, N1
Jain, L1
Venitz, J1
Figg, WD1
Stadler, W1
Blanke, C1
Oudard, S1
Solska, E1
Desai, AA1
Rolland, F1
Demkow, T1
Gore, M1
Freeman, S1
Simantov, R1
Flaherty, KT2
Sendi, P1
Puric, E1
Schönenberger, A1
Bargetzi, M1
Elser, C1
Siu, LL1
Winquist, E1
Agulnik, M1
Pond, GR1
Chin, SF1
Francis, P1
Cheiken, R1
Elting, J1
Petrenciuc, O1
Chen, EX1
Bingley, PJ1
Mahon, JL1
Gale, EA1
Chi, KN1
Ellard, SL1
Hotte, SJ1
Czaykowski, P1
Moore, M1
Ruether, JD1
Schell, AJ1
Taylor, S1
Hansen, C1
Gauthier, I1
Walsh, W1
Seymour, L1
Chu, D1
Lacouture, ME1
Fillos, T1
Wu, S1
Rosen, MA1
Heitjan, DF1
Gallagher, ML1
Schnall, MD1
O'Dwyer, PJ1
Bui, B1
Procopio, G1
Verzoni, E1
Gevorgyan, A1
Mancin, M1
Pusceddu, S1
Catena, L1
Platania, M1
Guadalupi, V1
Martinetti, A1
Bajetta, E1
Piercy, V1
Toseland, CD1
Turner, NC1

Clinical Trials (86)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label, Dose-escalation and Expansion Phase 1/2a Clinical Trial to Assess the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors[NCT03292783]Phase 145 participants (Actual)Interventional2017-09-18Completed
Neoadjuvant Combination Therapy of Lenvima Plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients With Large Hepatocellular Carcinoma[NCT05171335]Phase 250 participants (Anticipated)Interventional2022-06-20Enrolling by invitation
Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969]Phase 223 participants (Anticipated)Interventional2023-06-05Not yet recruiting
Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial[NCT01545804]Phase 255 participants (Actual)Interventional2011-08-31Completed
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial[NCT04244630]Phase 260 participants (Anticipated)Interventional2022-04-01Recruiting
Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients[NCT04654689]Phase 290 participants (Actual)Interventional2021-11-20Completed
A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma[NCT00334282]Phase 3435 participants (Actual)Interventional2006-04-30Completed
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636]Phase 2160 participants (Actual)Interventional2007-06-30Completed
Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors[NCT00942682]Phase 121 participants (Actual)Interventional2009-07-31Completed
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies[NCT00215605]Phase 185 participants (Actual)Interventional2005-09-30Completed
Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers[NCT00244972]Phase 174 participants (Actual)Interventional2005-10-31Completed
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma[NCT00121680]Phase 1115 participants (Actual)Interventional2005-07-31Completed
A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor[NCT00495872]Phase 1204 participants (Actual)Interventional2007-06-30Completed
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy[NCT00474786]Phase 3512 participants (Actual)Interventional2007-09-30Completed
SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.[NCT00989469]Phase 1/Phase 264 participants (Actual)Interventional2009-02-28Completed
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1[NCT03829462]Phase 378 participants (Anticipated)Interventional2019-03-28Recruiting
Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma[NCT00712790]Phase 1/Phase 235 participants (Actual)Interventional2008-06-30Completed
A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma[NCT00387751]Phase 214 participants (Actual)Interventional2006-08-31Completed
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949]Phase 1/Phase 239 participants (Anticipated)Interventional2019-12-01Not yet recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587]Early Phase 160 participants (Anticipated)Interventional2021-07-01Enrolling by invitation
A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study[NCT01035229]Phase 3546 participants (Actual)Interventional2010-04-30Completed
A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma[NCT01482442]Phase 3496 participants (Actual)Interventional2011-12-31Completed
A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00068289]Phase 20 participants Interventional2003-09-30Completed
A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00182689]Phase 289 participants (Actual)Interventional2005-07-31Completed
A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)[NCT00828139]Phase 2189 participants (Actual)Interventional2009-05-31Completed
A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma[NCT01804374]Phase 238 participants (Actual)Interventional2011-06-30Completed
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial[NCT04521153]290 participants (Anticipated)Interventional2021-03-25Recruiting
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697]Phase 3290 participants (Anticipated)Interventional2016-01-31Recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.[NCT00692770]Phase 31,114 participants (Actual)Interventional2008-08-15Completed
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation in Curative Intent: French Multicenter Phase 2 Therapeutic[NCT06045975]Phase 230 participants (Anticipated)Interventional2023-12-04Not yet recruiting
Adjuvant Tislelizumab With or Without Lenvatinib for Patients at High-risk of Hepatocellular Carcinoma Recurrence After Curative Resection or Ablation: a Multicentric, Prospective Study[NCT05910970]Phase 3200 participants (Anticipated)Interventional2023-08-30Not yet recruiting
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375]Phase 2/Phase 3192 participants (Anticipated)Interventional2015-02-28Recruiting
A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304]52 participants (Actual)Interventional2016-04-30Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.)
Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143]Phase 230 participants (Anticipated)Interventional2021-12-31Not yet recruiting
Lenvatinib in Neo-adjuvant and Adjuvant Therapy for Poor-prognosis BCLC A HepatoCellular Carcinoma Treated by Percutaneous Ablation Procedure in a Curative Intent: Multicentre Pilot Therapeutic Trial[NCT05113186]Phase 250 participants (Anticipated)Interventional2022-02-02Recruiting
Immunotherapy by Nivolumab in Neoadjuvant and Adjuvant Setting in Patients With Advanced HCC Treated by Electroporation in Curative Intent: French Multicenter Phase 2 Therapeutic Trial.[NCT03630640]Phase 243 participants (Actual)Interventional2018-10-11Active, not recruiting
A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age[NCT00893373]Phase 2276 participants (Actual)Interventional2009-03-31Completed
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial[NCT05404516]Phase 288 participants (Anticipated)Interventional2020-01-01Recruiting
Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. A Randomized Controlled Trial[NCT04803019]Phase 3154 participants (Anticipated)Interventional2019-12-04Recruiting
A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens[NCT00801385]Phase 247 participants (Anticipated)Interventional2008-09-30Recruiting
Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)[NCT01411436]1,637 participants (Actual)Observational2009-05-31Completed
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib[NCT01375569]Phase 211 participants (Actual)Interventional2011-06-22Completed
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625]Phase 4288 participants (Actual)Interventional2016-01-28Completed
Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib[NCT02786342]160 participants (Anticipated)Observational2016-02-15Active, not recruiting
Combining Radiation Therapy With Anti-PD-1 for Patients With Advanced Hepatocellular Carcinoma (RT+PD-1-HCC)[NCT04193696]Phase 239 participants (Anticipated)Interventional2020-01-10Not yet recruiting
TACE Combined With Iodine-125 Seeds Implantation Versus TACE Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective, Multicenter, Randomized, Controlled Study[NCT03322280]270 participants (Anticipated)Interventional2018-07-01Active, not recruiting
A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma[NCT00105443]Phase 3602 participants (Actual)Interventional2005-03-31Completed
Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy Followed by ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy (START-FIT)[NCT03817736]Phase 233 participants (Actual)Interventional2019-03-01Active, not recruiting
A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846]Phase 2/Phase 312 participants (Anticipated)Interventional2023-07-31Recruiting
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma: A Single Arm, Nonrandomized, Single Center Clinical Study[NCT05048017]Phase 220 participants (Anticipated)Interventional2021-10-01Recruiting
A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma[NCT04443309]Phase 1/Phase 253 participants (Anticipated)Interventional2020-09-11Recruiting
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma: a Single-center, Single-arm, Non-randomized Clinical Study[NCT04368078]Phase 276 participants (Anticipated)Interventional2020-07-11Recruiting
Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study.[NCT03892577]3,000 participants (Anticipated)Observational [Patient Registry]2017-07-01Recruiting
A Real World Study of Regogfinib in the Treatment of Advanced Hepatocellular Carcinoma[NCT05557656]800 participants (Anticipated)Observational2023-01-05Not yet recruiting
A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)[NCT02311205]Phase 255 participants (Anticipated)Interventional2014-12-31Active, not recruiting
Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330]129 participants (Actual)Interventional2014-03-21Completed
Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma[NCT01897610]Phase 240 participants (Actual)Interventional2013-12-31Completed
Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486]Phase 2160 participants (Actual)Interventional2011-11-14Completed
Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis[NCT03518502]Phase 4130 participants (Anticipated)Interventional2012-03-01Recruiting
Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion[NCT02436902]Phase 3240 participants (Anticipated)Interventional2019-02-01Recruiting
Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.[NCT05166239]Phase 266 participants (Anticipated)Interventional2022-01-10Recruiting
Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics[NCT02973204]167 participants (Actual)Observational [Patient Registry]2016-11-30Completed
Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone: a Multi-center Retrospective Study for Standardization and Modification of Response Evaluation Criteria[NCT03742063]190 participants (Actual)Observational2017-06-01Completed
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307]Phase 3903 participants (Actual)Interventional2003-11-30Completed
A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.[NCT00108953]Phase 296 participants (Actual)Interventional2005-04-30Completed
Phase II Trial of Regorafenib in Patients With Unresectable Hepatocellular Carcinoma After Progression on First Line Atezolizumab Plus Bevacizumab (REGONEXT Trial)[NCT05134532]Phase 240 participants (Anticipated)Interventional2021-12-24Active, not recruiting
Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739]Phase 2/Phase 3110 participants (Actual)Interventional2015-03-31Active, not recruiting
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)[NCT00494299]Phase 3458 participants (Actual)Interventional2006-04-30Completed
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies[NCT02787954]10 participants (Actual)Observational [Patient Registry]2016-01-31Terminated (stopped due to PI transferred to another institution and did not take this study with him.)
Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma[NCT02630108]Phase 3280 participants (Anticipated)Interventional2015-12-31Recruiting
Stereotactic Image-Guided Microwave Ablation for Hepatocellular Carcinoma - Does Computer-assistance Broaden Eligibility and Efficacy of Ablative Treatment?[NCT03630068]87 participants (Actual)Observational2015-01-01Completed
Radiofrequency Ablation or Surgical Resection Combined With Neo-MASCT for Primary Hepatocellular Carcinoma: a Randomised, Multicentre Phase II Trial[NCT03067493]Phase 298 participants (Anticipated)Interventional2017-07-25Recruiting
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab[NCT04954339]Phase 245 participants (Anticipated)Interventional2021-10-29Recruiting
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Ce[NCT00449033]Phase 3904 participants (Actual)Interventional2007-02-28Completed
Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors[NCT00984425]Phase 130 participants (Actual)Interventional2009-09-30Completed
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme[NCT00445588]Phase 256 participants (Actual)Interventional2007-01-31Completed
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809]Phase 440 participants (Anticipated)Interventional2014-01-31Recruiting
A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma[NCT00480935]Phase 23 participants (Actual)Interventional2007-10-31Terminated (stopped due to poor recruitment)
Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma.[NCT00941967]Phase 278 participants (Actual)Interventional2008-12-31Completed
Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatm[NCT00619268]Phase 2160 participants (Anticipated)Interventional2008-02-29Completed
SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors[NCT00933777]Phase 136 participants (Actual)Interventional2009-07-31Completed
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma[NCT01339975]310 participants (Anticipated)Observational2011-06-06Completed
Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors[NCT01202032]Phase 136 participants (Anticipated)Interventional2010-07-31Completed
Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study[NCT01762150]Phase 226 participants (Actual)Interventional2011-06-30Completed
A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer[NCT00093457]Phase 228 participants (Actual)Interventional2004-08-10Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Response

Duration of response is defined as the time from first observation of response until progression of disease or death. (NCT00334282)
Timeframe: Time from response until progression (up to 2 years)

Interventionweeks (Median)
Pazopanib 800 mg58.7

Overall Survival

Overall survival is defined as the time from randomization until death. The length of this interval was estimated as the date of death minus the date of randomization plus 1 day. Participants who were still alive at the time of analysis were censored. (NCT00334282)
Timeframe: Randomization until death (up to 2 years)

Interventionmonths (Median)
Pazopanib 800 mg22.9
Placebo20.5

Progression-free Survival

Progression-free survival (PFS) is defined as the interval between the date of randomization and the earliest date of disease progression or death due to any cause. Assessments of progression and non-progression were made by an independent imaging review committee (IRC) for the primary analysis. (NCT00334282)
Timeframe: Randomization until progression (up to 2 years)

Interventionmonths (Median)
Pazopanib 800 mg9.2
Placebo4.2

Adjusted Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ C-30) Score at Weeks 6, 12, 18, 24, and 48

The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer participants. The analyses for EORTC QLQ-C30 were focused on global health status/Health-Related Quality of Life (HRQOL) scores on the questionnaire. The scores (from 1 [very poor quality of life] to 7 [excellent quality of life]) for these two questions were averaged and then transformed to a 0 - 100 scale (based on published methods) prior to analysis of change from Baseline. (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48

,
Interventionpoints on a scale (Mean)
Week 6, n=243, 110Week 12, n=219, 81Week 18, n=191, 61Week 24, n=164, 49Week 48, n=96, 24
Pazopanib-3.2-3.6-2.50.1-0.3
Placebo-2.6-0.5-0.3-0.50.3

Adjusted Mean Change From Baseline in the Index Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48

The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index), through application of societal weights, and a VAS score (VAS). Index is interpreted on a continuum from 1.0 (best possible health) to 0 (represents dead), to some health sates being worse than dead (<0). (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48

,
Interventionpoints on a scale (Mean)
Week 6, n=253, 125Week 12, n=219, 86Week 18, n=196, 62Week 24, n=166, 51Week 36, n=98, 24
Pazopanib 800 mg-0.014-0.040-0.023-0.0250.030
Placebo-0.0290.007-0.006-0.001-0.005

Adjusted Mean Change From Baseline in the Visual Analog Scale (VAS) Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48

The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index) and a VAS score (VAS), obtained from participant's self-reports of their health on a VAS thermometer scale. The EQ-5D VAS ranges from 0% (worst imaginable health state) to 100% (best imaginable health state). (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48

,
Interventionpoints on a scale (Mean)
Week 12, n=212, 80Week 6, n=239, 111Week 18, n=189, 60Week 24, n=161, 49Week 36, n=95, 23
Pazopanib 800 mg-0.90.40.12.62.4
Placebo-3.60.20.15.48.8

Baseline Expression Levels of the Indicated Target Proteins in Pazopanib- and Placebo-treated Participants

Baseline plasma samples were obtained from participants and were tested for the indicated cytokine and angiogenesis factors. Protein levels were determined using the Searchlight multiplex system based on chemiluminescence. (NCT00334282)
Timeframe: Baseline

,
Interventionpicograms per milliliter (Mean)
Interleukin-6Interleukin-8Vascular endothelial growth factorHepatocyte growth factorTissue inhibitor of metalloproteinase 1e-SelectinOsteopotin
Pazopanib 800 mg31.00335.429308.61383.5584746441649.28444343
Placebo24.14527.755273.15522.9473591541231.45369317

Overall Response

Overall response is the number of participants who had a complete response (CR) or a partial response (PR). Per RECIST: CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the Baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a >=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease, small changes that do not meet previously given criteria. IRC, independent review committee. (NCT00334282)
Timeframe: Baseline until either response or progression (up to 2 years)

,
Interventionparticipants (Number)
Complete Response, IRC assessedPartial Response, IRC assessedStable Disease, IRC assessedProgressive Disease, IRC assessedUnknown, IRC assessedComplete Response, Investigator assessedPartial Response, Investigator assessedStable Disease, Investigator assessedProgressive Disease, Investigator assessedUnknown, Investigator assessed
Pazopanib 800 mg18711051414991184623
Placebo055958230962659

Participants With Complete Response, Partial Response, or 6 Months of Stable Disease

This is similar to overall response rate, but also includes participants who had stable disease for at least 6 months. Per Response Evaluation Criteria In Solid Tumors (RECIST): CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum; Stable Disease, small changes that do not meet previously given criteria; Progressive Disease, a >=20% increase in target lesions. IRC, independent review committee. (NCT00334282)
Timeframe: Baseline until 6 months post-Baseline or progressive disease

,
Interventionparticipants (Number)
Complete Response, IRC assessedPartial Response, IRC assessed6 Months Stable Disease, IRC assessedProgressive Disease, IRC assessedUnknown
Pazopanib 800 mg187489262
Placebo05178439

Plasma Pazopanib Concentrations Before Dosing and at 2, 4, and 8 Hours After Dosing on Day 1 and Week 3

The concentration of pazopanib in the plasma was measured. (NCT00334282)
Timeframe: Day 1 and Week 3

Interventionnanograms per milliliter (Median)
Day 1, before dosing, n=57Week 3, before dosing, n=48Day 1, 2 hours after dosing, n=57Week 3, 2 hours after dosing, n=49Day 1, 4 hours after dosing, n=57Week 3, 4 hours after dosing, n=49Day 1, 8 hours after dosing, n=57Week 3, 8 hours after dosing, n=48
Pazopanib 800 mg031851172704220524360426371992540177.5

Time to Response as Assessed by an Independent Review Committee (IRC) and the Investigator

Time to response is defined as the time from randomization until the first documented evidence of complete response (all detectable tumor has disappeared) or partial response (a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum) (whichever status was recorded first). (NCT00334282)
Timeframe: Randomization until CR or PR (assessed for up to 2 years)

Interventionweeks (Median)
IRC assessed, n=88Investigator assessed, n=103
Pazopanib 800 mg11.912.0

Duration of Overall Response

Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)94
B (Placebo + Gemcitabine or Capecitabine)147

Overall Response Rate

Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.

Interventionpercentage of participants (Number)
A (Sorafenib + Gemcitabine or Capecitabine)19.8
B (Placebo + Gemcitabine or Capecitabine)12.7

Overall Survival

(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)407
B (Placebo + Gemcitabine or Capecitabine)348

Progression Free Survival

(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)103
B (Placebo + Gemcitabine or Capecitabine)81

Time to Progression

(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)111
B (Placebo + Gemcitabine or Capecitabine)82

Duration of Response (DR)

Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented. Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method. (NCT00474786)
Timeframe: Baseline up to 24 Months

Interventionmonths (Median)
Temsirolimus8.26
Sorafenib6.96

Overall Survival (OS)

Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact. (NCT00474786)
Timeframe: Baseline to date of death from any cause (up to 24 months)

Interventionmonths (Median)
Temsirolimus12.27
Sorafenib16.64

Percentage of Participants With Tumor Response

Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review. CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response. PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. (NCT00474786)
Timeframe: Baseline up to 24 Months

Interventionpercentage of participants (Number)
Temsirolimus7.7
Sorafenib7.9

Progression Free Survival (PFS) by Investigator Assessment

Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first. (NCT00474786)
Timeframe: Baseline up to 24 Months

Interventionmonths (Median)
Temsirolimus5.43
Sorafenib4.14

Progression-Free Survival (PFS)

Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first. (NCT00474786)
Timeframe: Baseline up to 24 Months

Interventionmonths (Median)
Temsirolimus4.28
Sorafenib3.91

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. (NCT00474786)
Timeframe: Baseline up to 24 months

,
Interventionparticipants (Number)
Serious AEAny AE
Sorafenib86251
Temsirolimus103248

Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment

PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first. PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7. (NCT00474786)
Timeframe: Weeks 12, 24, and 36

,
Interventionpercentage of participants (Number)
Baseline to Week 12Week 13 to Week 24Week 25 to Week 36
Sorafenib36.720.111.2
Temsirolimus31.220.912.3

Response

"Clinical biologic activity of treatment, defined as the sum of complete response, partial response, and prolonged stable disease for ≥ 16 weeks, upon treatment with the combination of sorafenib and bevacizumab, in patients with advanced metastatic melanoma previously treated with immunotherapy or in previously untreated patients who are not appropriate candidates to receive IL-2-based treatment.~Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started of the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started." (NCT00387751)
Timeframe: 4 months

Interventionparticipants (Number)
Bevacizumab and Sorafenib11

Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance. (NCT01035229)
Timeframe: When 454 OS events were observed

InterventionMonths (Median)
Everolimus + Best Supportive Care (BSC)7.56
Placebo + Best Supportive Care7.33

Percentage of Participants With Disease Control Rate (DCR)

DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient

InterventionPercentage of Participants (Number)
Everolimus + Best Supportive Care (BSC)56.1
Placebo + Best Supportive Care45.1

Pharmacokinetics Assessments - Cmax

Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.

Interventionng/mL (Mean)
Everolimus 7.5mg + Best Supportive Care (BSC)47.881
Everolimus 5mg + Best Supportive Care (BSC)31.592

Pharmacokinetics Assessments - Cmin

Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.

Interventionng/mL (Mean)
Everolimus 7.5mg + Best Supportive Care (BSC)16.141
Everolimus 5mg + Best Supportive Care (BSC)9.318

Time to Definitive Deterioration of ECOG Performance Score (PS) Score

Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.

InterventionMonths (Median)
Everolimus + Best Supportive Care (BSC)4.27
Placebo + Best Supportive Care4.47

Time to Definitive Deterioration of EORTC QLQ-C30 Scores

The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.

InterventionMonths (Median)
Everolimus + Best Supportive Care (BSC)2.86
Placebo + Best Supportive Care3.45

Time to Tumor Progression (TTP)

TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient

InterventionMonths (Median)
Everolimus + Best Supportive Care (BSC)2.96
Placebo + Best Supportive Care2.60

Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST)

Complete Response (CR) is a complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. (NCT00182689)
Timeframe: 8 weeks to 2 years

Interventionpercentage of participants (Number)
Platinum-Sensitive11
Platinum-Refractory2

Overall Survival

Measured from time of registration to death, or last contact date (NCT00182689)
Timeframe: 0 - 2 years

Interventionmonths (Median)
Platinum-Sensitive6.7
Platinum-Refractory5.3

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00182689)
Timeframe: Patients were assessed for adverse events after completion of every 28-day cycle.

,
InterventionParticipants with a given type of AE (Number)
AST, SGOTAllergic reaction/hypersensitivityAnorexiaAtaxia (incoordination)Bilirubin (hyperbilirubinemia)ConfusionDehydrationDiarrheaDizzinessDyspnea (shortness of breath)Fatigue (asthenia, lethargy, malaise)Fever in absence of neutropenia, ANC lt1.0x10e9/LHemoglobinHypertensionINR (of prothrombin time)Inf w/normal ANC or Gr 1-2 neutrophils - SkinInf w/normal ANC or Gr 1-2 neutrophils - UTILipaseMuscle weakness, not d/t neuropathy - body/generalNauseaNeuropathy: sensoryPTT (Partial thromboplastin time)Pain - Abdomen NOSPain - Extremity-limbPain - JointPain-Other (Specify)PancreatitisPhosphate, serum-low (hypophosphatemia)Pleural effusion (non-malignant)Pneumonitis/pulmonary infiltratesPotassium, serum-low (hypokalemia)Rash/desquamationRash: acne/acneiformRash: erythema multiformeRash: hand-foot skin reactionSodium, serum-low (hyponatremia)Speech impairment (e.g., dysphasia or aphasia)Syncope (fainting)VomitingWeight loss
Platinum Refractory0111122200311000111101211111100201821011
Platinum Sensitive1020010013500311000110101101011120910100

Overall Survival

Estimated to within at least 15% (95% confidence interval). (NCT00828139)
Timeframe: Weekly, up to 2 years.

Interventionmonths (Median)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept6.0
Platinum Sensitivity Treated With Topotecan Alone4.6
Platinum Refractory Treated With Topotecan + Ziv-aflibercept4.6
Platinum Refractory Treated With Topotecan Aloine4.2

Progression-free Survival (PFS)

"From the date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause.~Progression is defined as 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration." (NCT00828139)
Timeframe: Disease assessments were performed every 6 weeks, up to 2 years.

InterventionMonths (Median)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept1.8
Platinum Sensitivity Treated With Topotecan Alone1.3
Platinum Refractory Treated With Topotecan + Ziv-aflibercept1.4
Platinum Refractory Treated With Topotecan Aloine1.4

Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses)

"The number of confirmed and unconfirmed complete and partial responses in the subset of patients with measurable disease per RECIST 1.0. Estimated to within at least 17% (95% confidence interval).~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00828139)
Timeframe: Disease assessment for response were performed every 6 weeks, up to 2 years.

Interventionproportion of participants (Number)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept0.02
Platinum Sensitivity Treated With Topotecan Alone0
Platinum Refractory Treated With Topotecan + Ziv-aflibercept0.02
Platinum Refractory Treated With Topotecan Aloine0

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs

Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. The events listed here are not necessary to be included in Serious Adverse Event. A serious event could be death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly...Grade 3 through 5 adverse event may not meet the criterion of serious adverse event. (NCT00828139)
Timeframe: Toxicity assessment was evaluated after each cycle (21 days), up to 2 years.

,
InterventionParticipants (Number)
AST, SGOTAnorexiaBilirubin (hyperbilirubinemia)Bronchospasm, wheezingCalcium, serum-high (hypercalcemia)Cardiac-ischemia/infarctionColitis, infectious (e.g., Clostridium difficile)ConfusionConstipationCreatinineDehydrationDiarrheaDizzinessDyspnea (shortness of breath)Fatigue (asthenia, lethargy, malaise)Febrile neutropeniaGGT (gamma-glutamyl transpeptidase)HemoglobinHemolysisHemorrhage, GI - Upper GI NOSHemorrhage, pulmo/upper resp- Bronchopulmonary NOSHemorrhage, pulmonary/upper respiratory - LungHemorrhage, pulmonary/upper respiratory - NoseHypertensionINR (of prothrombin time)Inf (clin/microbio) w/Gr 3-4 neuts - ColonInf (clin/microbio) w/Gr 3-4 neuts - LungInf w/normal ANC or Gr 1-2 neutrophils - BronchusInf w/normal ANC or Gr 1-2 neutrophils - LungInf w/normal ANC or Gr 1-2 neutrophils - UTIInfection with unknown ANC - BloodInfection with unknown ANC - Lung (pneumonia)Left ventricular systolic dysfunctionLeukocytes (total WBC)Leukoencephalopathy (radiolographic findings)LipaseLymphopeniaMucositis/stomatitis (clinical exam) - Oral cavityMuscle weakness, not d/t neuropathy - body/generalNauseaNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - Chest wallPain - Head/headachePain - Pain NOSPlateletsPneumonitis/pulmonary infiltratesPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)ProteinuriaPsychosis (hallucinations/delusions)Renal failureSeizureSodium, serum-high (hypernatremia)Sodium, serum-low (hyponatremia)Syndromes-Other (Specify)Thrombosis/thrombus/embolismVoice changes/dysarthriaVomitingWeight loss
Topotecan2201000011101130071000000010012002200130112300001711101201100000
Ziv-aflibercept + Topotecan1310111300612715119121123110110011171151343031212900310010612121

Overall Survival (OS)

"OS was defined as the time from randomization to date of death due to any cause. OS for subjects alive at the time of analysis was censored at their last date of contact. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization of the first subject until 4 years later.

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)NA
PlaceboNA

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D Index is a descriptive system of the following health dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Subjects were asked to choose any one of the 3 response levels for each dimension: no problems, some problems, and severe problems. The 5 health dimensions were summarized into a single score, the EQ-5D Index score which ranged from -0.59 to 1 with higher scores representing better health states (0=death, 1= perfect health, and -0.59=a health state worse than death). A change of at least 0.10 to 0.12 points was considered a minimally important difference using Eastern Cooperative Oncology Group Performance Status as the anchor. The results on the Analysis of covariance of timeadjusted Area under curve for the EQ-5D index score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

InterventionUnit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)0.827
Placebo0.866

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D VAS is a measure that represents health status as a single value. It is a 20-centimetre vertical graduated visual analogue scale with scores that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). The respondent rated his/her current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the EQ-5D VAS. A 3-digit number (including leading zeros) was read off the scale from the point where the respondent's line crossed the scale, which was the EQ-5D VAS score. A change of at least 7 points on the VAS was considered as minimally important. The results on the ANCOVA analysis of time-adjusted AUC for the EQ-5D VAS score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

InterventionUnit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)77.203
Placebo80.181

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- General (G) Total Score

The PWB, FWB, SWB and EWB were summed to form the FACT-G total score. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). FACT-G scores ranged from 0 to 108 and the higher scores represented a better quality of life. The MID for the FACT-G total score was in the range of 6 to 7. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-G score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

InterventionUnit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)80.46
Placebo82.95

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- Hepatobiliary Subscale (HEP) Score

The FACT-HEP is a 45 item, self-administered, multi-dimensional, psychometrically sound questionnaire used extensively in oncology clinical trials. FACT-HEP consisted of five subscales: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The PWB, FWB, SWB and EWB were summed to form the FACTGeneral (FACT-G) total score. The FACT-G and HCS scores were summed to form the FACT-HEP total score. FACT-HEP scores ranged from 0 to 180 and the higher scores represented a better quality of life. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). The minimally important difference (MID) for the FACT-Hep total score was in the range of 8 to 9. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-HEP score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

InterventionUnit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)138.7
Placebo143.79

Recurrence Free Survival (RFS) by Independent Assessment

Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death. (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)1014
Placebo1026

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - AFP

"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline

InterventionDays (Median)
AFP High Expression Group668
AFP Low Expression Group1267

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - ANG-2

"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline

InterventionDays (Median)
ANG-2 High Expression Group588
ANG-2 Low Expression Group1260

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET

"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline

InterventionDays (Median)
MET High Expression Group841
MET Low Expression GroupNA

Time to Recurrence (TTR) by Independent Assessment

"TTR was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment. For subjects who had not recurred at the time of analysis, TTR was censored at their last date of evaluable scan before withdrawal for any other reason than recurrence. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)1172
Placebo1089

Count of Participants With Adverse Events

here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01375569)
Timeframe: 25 months, 15 days

InterventionParticipants (Count of Participants)
TRC105 in Liver Cancer11

Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).

Time to tumor progression is defined as the proportion of participants who are progression free after 4 months on study. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01375569)
Timeframe: 2 years

InterventionWeeks (Mean)
TRC105 in Liver Cancer12

Disease Control (DC)

The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease. (NCT00105443)
Timeframe: time from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment

InterventionParticipants (Number)
Sorafenib (Nexavar, BAY43-9006)130
Placebo96

Disease Control (DC)

The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment

InterventionParticipants (Number)
Sorafenib (Nexavar, BAY43-9006)130
Placebo96

Overall Survival

Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00105443)
Timeframe: from randomization to death due to any cause until an average 8.5 months later up to the data cut-off date approximately 23 months after start of enrollment

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)327
Placebo243

Overall Survival (OS)

Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00105443)
Timeframe: from randomization to death due to any cause until an average 7.2 months later up to the data cut-off date approximately 19 months after start of enrollment

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)324
Placebo241

Time to Progression (TTP)

TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00105443)
Timeframe: from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 19 months after start of enrollment

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)168
Placebo86

Time to Progression (TTP)

TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00105443)
Timeframe: from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 23 months after start of enrollment

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)168
Placebo86

Time to Symptomatic Progression (TTSP)

TTSP was defined as the time from randomization to the first documented symptomatic progression (NCT00105443)
Timeframe: from randomization to the first documented symptomatic progression until an average 5.7 months later up to the data cut-off date approximately 23 months after start of enrollment

InterventionDays (Median)
Sorafenib (Nexavar, BAY43-9006)127
Placebo148

Time to Symptomatic Progression (TTSP)

TTSP was defined as the time from randomization to the first documented symptomatic progression. (NCT00105443)
Timeframe: from randomization to the first documented symptomatic progression until an average 4.8 months later up to the data cut-off date approximately 19 months after start of enrollment

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)126
Placebo148

Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire

PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment

,
InterventionParticipants (Number)
Cycle 3 day 1 change <8 pointsCycle 3 day 1 change ≥8 points
Placebo13939
Sorafenib (Nexavar, BAY43-9006)15123

Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire

PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. At the cut-off date for this analysis, one more patient data has been gained. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment

,
InterventionParticipants (Number)
Cycle 3 day 1 change <8 pointsCycle 3 day 1 change ≥8 points
Placebo13940
Sorafenib (Nexavar, BAY43-9006)15123

Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population

Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)542
Placebo436

Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population

Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)542
Placebo461

Final Progression-Free Survival (PFS) - Independent Radiological Review

PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)167
Placebo84

Best Overall Response - Independent Radiological Review

Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

,
Interventionpercentage of participants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot Evaluated
Placebo0.00.055.230.314.5
Sorafenib (Nexavar, BAY43-9006)0.02.177.98.711.3

Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment

"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

,
InterventionScores on a scale (Least Squares Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 4, Day 1Cycle 5, Day 1Cycles 1-5 (Overall)
Placebo27.7827.2826.7826.2827.20
Sorafenib (Nexavar, BAY43-9006)27.7727.2726.7726.2727.19

Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment

"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

,
InterventionScores on a scale (Least Squares Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 4, Day 1Cycle 5, Day 1Cycles 1-5 (Overall)
Placebo21.1620.7220.2819.8420.65
Sorafenib (Nexavar, BAY43-9006)21.2120.7720.3319.8920.70

Duration of Response

Time from date of first objective response (complete response [CR] or partial response [PR]) to date progression is first documented (as defined per independent central radiological assessment) or death, whichever occurs first (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later

Interventiondays (Median)
Sorafenib + Doxorubicin199
Placebo + Doxorubicin68

Overall Survival

The time from date of randomization to date of death (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later

Interventiondays (Median)
Sorafenib + Doxorubicin418
Placebo + Doxorubicin199

Percentage of Participants for Whom Disease Control Was Achieved

Participants with disease control: those who have as best response complete response (CR), partial response (PR) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease) according to Response Evaluation Criteria in Solid Tumors (RECIST) (NCT00108953)
Timeframe: from date of randomization to end of treatment plus 30 days

InterventionPercentage of participants (Number)
Sorafenib + Doxorubicin63.8
Placebo + Doxorubicin30.6

Progression Free Survival (PFS)

Time from the date of randomization to the date of the first documented radiological progression (as defined per independent central radiological assessment) or death, whichever occurs first (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later

Interventiondays (Median)
Sorafenib + Doxorubicin242
Placebo + Doxorubicin85

Time to Progression (TTP)

TTP was defined as the time from randomization to radiological disease progression by independent assessment. (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later

Interventiondays (Median)
Sorafenib + Doxorubicin263
Placebo + Doxorubicin147

Time to Response (TTR)

Time from date of randomization to date of first objective response (complete response [CR] or partial response [PR]) is documented and confirmed according to RECIST criteria (NCT00108953)
Timeframe: from date of randomization until 3 years later at end of study

Interventiondays (Median)
Sorafenib + Doxorubicin134
Placebo + Doxorubicin40

Time to Symptomatic Progression (TTSP)

Time from date of randomization to date of first documented symptomatic progression defined by Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index-8 (FHSI-8) assessment (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later

Interventiondays (Median)
Sorafenib + Doxorubicin208
Placebo + Doxorubicin152

Percentage of Participants in Each Category of Best Tumor Response

Percentage of participants with complete or partial response (CR or PR) confirmed according to Response Evaluation Criteria in Solid Tumors (RECIST) and achieved during treatment or 30 days after end of treatment. CR: disappearance of all clinical and radiological tumor lesions. PR: at least 30% decrease in sum of the longest diameters of tumor lesions. Stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease. (NCT00108953)
Timeframe: achieved during treatment or within 30 days after termination of active therapy

,
InterventionPercentage of participants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)
Placebo + Doxorubicin2.00.049.0
Sorafenib + Doxorubicin0.04.366.0

Time to Progression (TTP)

Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00494299)
Timeframe: From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)164
Placebo112

Number of Death Cases Due to Any Cause

(NCT00494299)
Timeframe: From randomization of the first subject until death due to any cause assessed up to 55 months.

,
InterventionParticipants (Number)
up to 39 monthsup to 55 months
Placebo4156
Sorafenib (Nexavar, BAY43-9006)4350

Disease Control (DC) in the ITT (Non-squamous) Population

DC was defined as the total number of patients whose best response was not PD according to RECIST (version 1.0) by Investigator-assessment (= total number of CR + total number of PR + total number of SD; CR or PR had to be maintained for at least 28 days from the first demonstration of that rating, SD had to be documented at least once more than 6 weeks from baseline). PD: an increase in the sum of tumor lesions sizes or new lesions. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

Interventionpercentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006) + GC62.1
Placebo + GC63.1

Duration of Response in the ITT (Non-squamous) Population

Duration of response was defined as the time from date of first documented objective response of PR or CR, whichever was noted earlier, to date of disease progression or death (if death occurred before progression was documented). Patients without disease progression at the time of analysis or death before progression were censored at the last date of tumor evaluation. Disease progression: increase in the sum of tumor lesion sizes or new lesions. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC171
Placebo + GC133

Duration of Stable Disease (SD) in the ITT (Non-squamous) Population

Duration of SD was defined as the time from date of randomization to date that disease progression (radiological or clinical, whichever was earlier) was first documented. Patients without disease progression at the time of analysis or death before progression were censored at the date of their last tumor assessment.(Disease progression: increase in the sum of tumor lesion sizes or new lesions.) Duration of stable disease was only evaluated in patients failing to achieve a best response of CR or PR. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC144
Placebo + GC131

OS in the ITT (Both Squamous and Non-squamous) Population

OS was defined as the time from date of randomization to death due to any cause. Patients still alive at the time of analysis were censored at their last date of last contact. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death of any cause whichever came first

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC371
Placebo + GC378

OS in the ITT (Squamous) Population

OS was defined as the time from date of randomization to death due to any cause. Patients still alive at the time of analysis were censored at their last date of last contact. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death of any cause whichever came first

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC254
Placebo + GC374

Overall Survival (OS) in the ITT (Non-squamous) Population

Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Patients still alive at the time of analysis were censored at their last date of last contact. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death of any cause whichever came first

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC376
Placebo + GC379

Progression-free Survival (PFS) in the ITT (Non-squamous) Population

PFS was defined as the time from date of randomization to disease progression (radiological or clinical, whichever was earlier, based on Investigator-assessment using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0) or death due to any cause, whichever occured first. Patients without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression: increase in the sum of tumor lesion sizes or new lesions. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC183
Placebo + GC168

Time to Progression (TTP) in the ITT (Non-squamous) Population

TTP was defined as the time from date of randomization to disease progression (radiological or clinical, whichever was earlier, based on Investigator-assessment using RECIST version 1.0). Patients without progression at the time of analysis or death before progression were censored at their last date of tumor evaluation. Disease progression: increase in the sum of tumor lesion sizes or new lesions. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC185
Placebo + GC167

Time to Response (TTR) in the ITT (Non-squamous) Population

TTR for patients who achieved a best response (CR or PR) was defined as the time from date of randomization to the earliest date that response was first documented. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death of any cause whichever came first

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + GC42
Placebo + GC43

Time to Symptomatic Deterioration (TSD) in the ITT (Non-squamous) Population

TSD is defined as the time from randomization to the date of symptomatic deterioration (≥3 point decline in the LCS score that is maintained for at least 2 consecutive cycles) or death if death occurs before these 2 consecutive cycles are completed. (NCT00449033)
Timeframe: from randomization of the first patient to 38 months later or death whatever occurs first

Interventionmonths (Median)
Sorafenib (Nexavar, BAY43-9006) + GC6.9
Placebo + GC4.5

EQ-5D Visual Analog Scale (VAS) Scores in the ITT (Non-squamous) Population

The EQ-5D also contains a visual analog scale (EQ-VAS), which records the respondent's self-rated health status on a vertical graduated visual analog scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00449033)
Timeframe: from randomization of the first patient until 38 months later or death whatever occurs first

,
Interventionscores on a scale (Least Squares Mean)
cycle 1 (day 1)cycle 2 (day 22)cycle 3 (day 43)cycle 4 (day 64)cycle 5 (day 85)cycle 6 (day 106)
Placebo + GC68.9668.9668.9568.9568.9568.95
Sorafenib (Nexavar, BAY43-9006) + GC66.4366.4366.4366.4366.4266.42

Euro Quality of Life - 5D (EQ-5D) Index Scores in the ITT (Non-squamous) Population

The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 to 1 when the United Kingdom (UK) weights are applied (0=death, 1=perfect health). Higher index scores represent better health states. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months later or death whatever occurs first

,
Interventionscores on a scale (Least Squares Mean)
cycle 1 (day 1)cycle 2 (day 22)cycle 3 (day 43)cycle 4 (day 64)cycle 5 (day 85)cycle 6 (day 106)
Placebo + GC0.760.750.750.740.730.73
Sorafenib (Nexavar, BAY43-9006) + GC0.700.690.690.680.680.67

Functional Assessment of Cancer Treatment-Lung (FACT-L) Scores in the ITT (Non-squamous) Population

The FACT-L measures health related quality of life (HRQOL) and composes of five domains: the four domains (physical well being, emotional well being, social well being, functional well being) from the Functional Assessment of Cancer Treatment-General scale (FACT-G) and the lung cancer subscale (LCS). The FACT-L total score ranges from 0 to 136, higher scores represent better HRQOL. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months

,
Interventionscores on a scale (Least Squares Mean)
cycle 2 (day 22)cycle 4 (day 64)cycle 6 (day 106)
Placebo + GC94.093.693.1
Sorafenib (Nexavar, BAY43-9006) + GC90.690.189.7

Lung Cancer Subscale (LCS) Scores in the ITT (Non-squamous) Population

LCS is a subscale of FACT-L measuring lung cancer specific symptoms. The LCS scores range from 0 to 28, higher scores represent fewer lung cancer symptoms. (NCT00449033)
Timeframe: from randomization of the first patient to 38 months later or death whatever occurs first.

,
Interventionscores on a scale (Least Squares Mean)
cycle 1 (day 1)cycle 2 (day 22)cycle 3 (day 43)cycle 4 (day 64)cycle 5 (day 85)cycle 6 (day 106)
Placebo + GC20.520.520.420.320.320.2
Sorafenib (Nexavar, BAY43-9006) + GC20.019.919.919.819.719.7

Percentage of Participants With Different Tumor Response in the ITT (Non-squamous) Population

Tumor response (= Best Overall Response) of a patient was defined as the best tumor response (confirmed Complete Response (CR: disappearance of tumor lesions), confirmed Partial Response (PR: a decrease of at least 30% in the sum of tumor lesion sizes), Stable Disease (SD: steady state of disease), or Progressive Disease (PD: an increase in the sum of tumor lesions sizes or new lesions)) observed during trial period assessed according to the RECIST criteria (version 1.0) based on Investigator-assessment. (NCT00449033)
Timeframe: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks

,
Interventionpercentage of participants (Number)
CRconfirmed PRSDPDNot assessable
Placebo + GC0.025.837.217.119.9
Sorafenib (Nexavar, BAY43-9006) + GC0.027.834.310.927.0

6months -Progression-free Survival Rate

defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up (NCT00445588)
Timeframe: At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up

Interventionpercentage of participants (Number)
Treatment14

Overall Survival

death. measured by time of first day of treatment until date of death, assessed up to 2 years. (NCT00445588)
Timeframe: Time of first day of the treatment to death, assessed up to 2 years

Interventionmonths (Median)
Treatment5.7

Reviews

43 reviews available for niacinamide and Disease Exacerbation

ArticleYear
New and current preventive treatment options in actinic keratosis.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2017, Volume: 31 Suppl 5

    Topics: Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Keratosis, Actinic; Male; Niacinamide

2017
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand

2018
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
    Expert review of anticancer therapy, 2017, Volume: 17, Issue:12

    Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds

2017
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    BMC gastroenterology, 2018, Sep-04, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality

2018
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Di

2013
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
    International urology and nephrology, 2013, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progr

2013
Sorafenib in metastatic thyroid cancer: a systematic review.
    The oncologist, 2014, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male

2014
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality

2014
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progressio

2014
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
    World journal of gastroenterology, 2014, Apr-21, Volume: 20, Issue:15

    Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor

2014
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
    Cancer cell, 2014, May-12, Volume: 25, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression;

2014
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy

2014
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Molecular biology reports, 2014, Volume: 41, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality

2014
Refining sorafenib therapy: lessons from clinical practice.
    Future oncology (London, England), 2015, Volume: 11, Issue:3

    Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Mo

2015
Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
    Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:4

    Topics: Abatacept; Antibodies, Monoclonal, Humanized; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus

2014
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Di

2014
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; D

2015
[Advanced hepatocellular carcinoma: importance of clinical trials].
    Revue medicale suisse, 2015, May-20, Volume: 11, Issue:475

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disea

2015
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
    World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epige

2015
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-18, Volume: 21

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Diseas

2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
    Aktuelle Urologie, 2015, Volume: 46, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Diseas

2015
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibi

2016
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:6

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neopla

2016
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
    Expert review of anticancer therapy, 2016, Volume: 16, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Ne

2016
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niac

2016
Recent advances in hepatocellular carcinoma therapy.
    Pharmacology & therapeutics, 2017, Volume: 173

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality

2017
[Oncology 2008].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
[Value of targeted therapies for renal cell cancer].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
Current management of hepatocellular carcinoma.
    The Medical clinics of North America, 2009, Volume: 93, Issue:4

    Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Ther

2009
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Onkologie, 2010, Volume: 33 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom

2010
Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease

2010
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:13

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2010
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Endocrine journal, 2011, Volume: 58, Issue:3

    Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; P

2011
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
    Clinical and experimental immunology, 2012, Volume: 167, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; C

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic;

2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theo

2013
BAY 43-9006: preclinical data.
    Current pharmaceutical design, 2002, Volume: 8, Issue:25

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Disease Progression; Humans; Mice;

2002
[Multicenter randomized trial on prevention of type 1 diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9

    Topics: Autoantibodies; Biomarkers; Diabetes Mellitus, Type 1; Disease Progression; Glutamate Decarboxylase;

2002
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25 Suppl 2

    Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therap

2005
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II

2006
Sorafenib in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease P

2007
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions

2008
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm

2008

Trials

57 trials available for niacinamide and Disease Exacerbation

ArticleYear
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109S

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-

2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor;

2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor;

2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor;

2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor;

2017
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
    Japanese journal of clinical oncology, 2018, Apr-01, Volume: 48, Issue:4

    Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms;

2018
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
    Journal of vascular and interventional radiology : JVIR, 2018, Volume: 29, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2018
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 20, Issue:1-2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El

2019
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 20, Issue:1-2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El

2019
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 20, Issue:1-2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El

2019
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 20, Issue:1-2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El

2019
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Phar

2013
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Everolimus; Feasibility Studies

2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
    Cancer, 2013, Jul-15, Volume: 119, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc

2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Anticancer research, 2013, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2013
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, 03-10, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression;

2014
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
    Head & neck, 2015, Volume: 37, Issue:2

    Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niac

2015
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization

2014
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
    Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

2014
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    JAMA, 2014, Jul-02, Volume: 312, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2014
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Trials, 2014, Dec-03, Volume: 15

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease

2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi

2015
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi

2015
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi

2015
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi

2015
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C

2015
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
    Investigational new drugs, 2016, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neo

2016
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease

2016
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou

2008
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom

2010
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
    Oncology, 2010, Volume: 78, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;

2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhy

2010
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacar

2011
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    British journal of cancer, 2010, Oct-12, Volume: 103, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonat

2010
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    JAMA, 2010, Nov-17, Volume: 304, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2010
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe

2010
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disea

2011
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
    PloS one, 2011, Feb-14, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio

2011
[Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antioxidants; Autoantibodies; Cognition; Disease Progres

2011
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:14

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom

2011
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Di

2012
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progress

2011
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma,

2011
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Dise

2012
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
    The oncologist, 2012, Volume: 17, Issue:3

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progress

2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Journal of hepatology, 2012, Volume: 57, Issue:4

    Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; F

2012
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-01, Volume: 30, Issue:25

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell L

2012
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Rela

2013
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Journal of digestive diseases, 2013, Volume: 14, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolizati

2013
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
    Neuro-oncology, 2013, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; E

2013
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progressio

2013
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Biopsy;

2005
Randomized discontinuation trial of sorafenib (BAY 43-9006).
    Cancer biology & therapy, 2006, Volume: 5, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind M

2006
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis

2007
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression

2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antin

2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression;

2008

Other Studies

193 other studies available for niacinamide and Disease Exacerbation

ArticleYear
Nicotinamide attenuates the decrease in dendritic spine density in hippocampal primary neurons from 5xFAD mice, an Alzheimer's disease animal model.
    Molecular brain, 2020, 02-07, Volume: 13, Issue:1

    Topics: Adenosine Monophosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Dendrit

2020
Physical exercise may exert its therapeutic influence on Alzheimer's disease through the reversal of mitochondrial dysfunction via SIRT1-FOXO1/3-PINK1-Parkin-mediated mitophagy.
    Journal of sport and health science, 2021, Volume: 10, Issue:1

    Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Brain-Derived Neurotrophic Factor;

2021
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021, 01-01, Volume: 36, Issue:1

    Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Disease Prog

2021
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
    International journal of molecular sciences, 2020, Dec-29, Volume: 22, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Bispecific; Apoptosis; Calcium-Binding Pr

2020
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
    Toxins, 2021, 01-11, Volume: 13, Issue:1

    Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism;

2021
Effect of NAD+ boosting on kidney ischemia-reperfusion injury.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Acute Kidney Injury; Animals; Autophagy; Disease Progression; Fibrosis; Glucuronidase; Kidney; Kloth

2021
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease P

2017
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:2

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular

2018
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
    Cell death & disease, 2017, 05-04, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyc

2017
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Oncotarget, 2017, Jul-18, Volume: 8, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Sid

2017
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
    Cancer science, 2017, Volume: 108, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Pro

2017
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Respo

2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free

2017
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-

2018
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Radiology, 2018, Volume: 287, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization,

2018
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co

2018
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
    BMC cancer, 2018, 03-20, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up

2018
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
    Oncology, 2018, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2018
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, May-23, Volume: 40, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival;

2018
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:25

    Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome

2018
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
    Anticancer research, 2018, Volume: 38, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplas

2018
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
    BMC cancer, 2018, Sep-18, Volume: 18, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Prolife

2018
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
    Nature, 2019, Volume: 569, Issue:7758

    Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cells, Cultured; Disease Progression; DNA Methylati

2019
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:3

    Topics: Acrylamides; Animals; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Cel

2013
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
    Oncology, 2013, Volume: 84, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Prog

2013
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
    Clinical pharmacology and therapeutics, 2013, Volume: 93, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, P

2013
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Animals; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Synergis

2013
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized;

2013
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Coh

2013
Model-based drug development in oncology: what's next?
    Clinical pharmacology and therapeutics, 2013, Volume: 93, Issue:4

    Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; M

2013
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease

2013
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle

2013
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
    Journal of gastroenterology, 2014, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2014
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Prog

2013
Impact of dementia progression on food-related processes: a qualitative study of caregivers' perspectives.
    American journal of Alzheimer's disease and other dementias, 2013, Volume: 28, Issue:6

    Topics: Adult; Aged; Caregivers; Dementia; Disease Progression; Eating; Feeding Behavior; Female; Friends; H

2013
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:7

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Diseas

2013
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Radiology, 2013, Volume: 269, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2013
Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
    Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:10

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progress

2013
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular

2014
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female;

2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
    World journal of surgical oncology, 2013, Sep-27, Volume: 11

    Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Human

2013
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Urologic oncology, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disea

2014
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Jan-07, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Journal of gastroenterology, 2014, Volume: 49, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studi

2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    The oncologist, 2014, Volume: 19, Issue:5

    Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Dis

2014
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
    International journal of clinical oncology, 2015, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Fema

2015
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Sur

2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
    Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeo

2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap

2014
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Sep-21, Volume: 20, Issue:35

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dise

2014
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
    American journal of clinical oncology, 2017, Volume: 40, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplas

2017
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
    Endocrine, 2015, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodi

2015
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule;

2014
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Femal

2015
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepa

2015
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control

2015
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    American journal of clinical pathology, 2015, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; D

2015
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Human

2015
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease

2015
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression;

2015
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Cancer medicine, 2015, Volume: 4, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery;

2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
    Science translational medicine, 2015, Jun-10, Volume: 7, Issue:291

    Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progres

2015
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
    Oncotarget, 2015, Sep-15, Volume: 6, Issue:27

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic;

2015
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:132

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diseas

2014
Systemic Treatment: Expecting Further Success.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; L

2015
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
    International journal of clinical oncology, 2016, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Fema

2016
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
    Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:9

    Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models

2015
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:6

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecul

2015
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemoki

2015
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; C

2015
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
    BMC cancer, 2015, Aug-28, Volume: 15

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Dise

2015
Streptozotocin-Induced Diabetic Models in Mice and Rats.
    Current protocols in pharmacology, 2015, Sep-01, Volume: 70

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet

2015
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Di

2015
Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
    Haematologica, 2016, Volume: 101, Issue:3

    Topics: Antineoplastic Agents; B-Lymphocytes; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemotaxi

2016
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Medicine, 2015, Volume: 94, Issue:49

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progres

2015
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut, 2017, Volume: 66, Issue:3

    Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progressi

2017
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Surviva

2016
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    Thyroid : official journal of the American Thyroid Association, 2016, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Sur

2016
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    International journal of clinical oncology, 2016, Volume: 21, Issue:4

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark

2016
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2016
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Radiology, 2016, Volume: 279, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2016
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival;

2016
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Jan-29, Volume: 16

    Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diff

2016
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Gastroenterology, 2016, Volume: 150, Issue:7

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Dr

2016
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Journal of gastroenterology, 2016, Volume: 51, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemic

2016
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Dise

2016
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    International journal of cancer, 2016, Aug-15, Volume: 139, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeuti

2016
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
    Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2016
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Apr-21, Volume: 22, Issue:15

    Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression;

2016
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit

2016
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
    Journal of hepatology, 2016, Volume: 65, Issue:2

    Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Human

2016
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Radiation oncology (London, England), 2016, May-18, Volume: 11

    Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Diseas

2016
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Femal

2016
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
    Oncotarget, 2016, 09-27, Volume: 7, Issue:39

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2016
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2016
Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.
    Respiratory research, 2016, 08-31, Volume: 17, Issue:1

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Case-Control Studies; Disease Models, Animal; Disease

2016
Sorafenib plus cisplatin for hepatocellular carcinoma.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial

2016
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-S

2017
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2016, Nov-15, Volume: 23, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort St

2016
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
    Trials, 2016, 11-25, Volume: 17, Issue:1

    Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disea

2016
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2017
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
    Cancer letters, 2017, 03-01, Volume: 388

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hyd

2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
    The American journal of case reports, 2017, Jan-03, Volume: 18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression

2017
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
    Autophagy, 2017, Mar-04, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neopla

2017
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellula

2017
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined

2016
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Oncology, 2017, Volume: 92, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease

2017
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cytokine, 2017, Volume: 95

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines

2017
[Targeted therapy for metastatic bladder cancer].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
[Systemic therapy of metastasizing renal cell carcinoma].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate

2008
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:4

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B;

2009
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Circulation, 2008, Nov-11, Volume: 118, Issue:20

    Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Re

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; H

2008
Motesanib diphosphate in progressive differentiated thyroid cancer.
    The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25

    Topics: Adenocarcinoma, Follicular; Biomarkers, Tumor; Disease Progression; Humans; Indoles; Mitogen-Activat

2008
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Anima

2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, R

2009
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Journal of the National Cancer Institute, 2009, Apr-15, Volume: 101, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Prolife

2009
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
    Clinical and experimental nephrology, 2009, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell;

2009
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II

2009
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carc

2010
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation;

2009
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates

2010
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans;

2010
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease

2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
    The oncologist, 2010, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;

2010
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures

2010
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disea

2010
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2010, Volume: 41, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antine

2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Dise

2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dru

2010
Effect of sorafenib on experimental choroidal neovascularization in the rat.
    Clinical & experimental ophthalmology, 2010, Volume: 38, Issue:7

    Topics: Animals; Benzenesulfonates; Choroidal Neovascularization; Computer Systems; Disease Progression; Dos

2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle

2011
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
    International journal of urology : official journal of the Japanese Urological Association, 2010, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt

2010
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Analytical and quantitative cytology and histology, 2010, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease

2010
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
    International journal of urology : official journal of the Japanese Urological Association, 2010, Volume: 17, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Hum

2010
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Li

2010
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio

2010
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:8

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoemb

2010
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    BJU international, 2011, Volume: 108, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates;

2011
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C

2012
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
    Laboratory investigation; a journal of technical methods and pathology, 2011, Volume: 91, Issue:4

    Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line,

2011
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    JAMA, 2011, Feb-23, Volume: 305, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubici

2011
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:7

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Fem

2011
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
    Bulletin du cancer, 2011, Volume: 98, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cont

2011
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Urologic oncology, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma,

2013
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    World journal of urology, 2011, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administr

2011
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, R

2011
Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth.
    Journal of cellular physiology, 2012, Volume: 227, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Disease Models, Animal; Di

2012
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    World journal of urology, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles;

2013
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disea

2011
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
    BMC gastroenterology, 2011, May-12, Volume: 11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Hum

2011
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
    World journal of gastroenterology, 2011, May-21, Volume: 17, Issue:19

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dise

2011
Severe sorafenib-induced hand-foot skin reaction.
    Dermatology online journal, 2011, May-15, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Dis

2011
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio

2012
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2011, Volume: 42, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma,

2011
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hu

2011
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
    Digestive diseases (Basel, Switzerland), 2011, Volume: 29, Issue:3

    Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progressi

2011
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
    Journal of clinical immunology, 2011, Volume: 31, Issue:6

    Topics: Animals; Anisoles; Astrocytes; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Proliferati

2011
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug

2011
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Onkologie, 2011, Volume: 34, Issue:10

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatoce

2011
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Disease Progression

2012
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; C

2011
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1

    Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; D

2012
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:5

    Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Ou

2012
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Radiology, 2012, Volume: 263, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular;

2012
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    American journal of clinical oncology, 2013, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Fa

2013
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease

2012
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;

2012
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2012
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, He

2012
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Oncology, 2012, Volume: 83, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomar

2012
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Hum

2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemothe

2013
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
    Oncology, 2013, Volume: 84, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease

2013
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    World journal of gastroenterology, 2012, Oct-28, Volume: 18, Issue:40

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease P

2012
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
    Acta radiologica (Stockholm, Sweden : 1987), 2013, Mar-01, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; H

2013
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
    Anti-cancer drugs, 2013, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular

2013
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2012
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
    TheScientificWorldJournal, 2012, Volume: 2012

    Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; F

2012
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, T

2013
Clinical trials. Diabetes' brave new world.
    Science (New York, N.Y.), 2003, Jun-20, Volume: 300, Issue:5627

    Topics: Adolescent; Adult; Autoantibodies; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Disea

2003
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer research, 2004, Oct-01, Volume: 64, Issue:19

    Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum

2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer research, 2004, Oct-01, Volume: 64, Issue:19

    Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum

2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer research, 2004, Oct-01, Volume: 64, Issue:19

    Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum

2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer research, 2004, Oct-01, Volume: 64, Issue:19

    Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum

2004
Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:7

    Topics: Adenine; Animals; Disease Models, Animal; Disease Progression; Intestinal Mucosa; Intestines; Kidney

2005
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Servic

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog

2006
New therapeutic options for renal cell carcinoma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma,

2006
Current and future management of GIST.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Respo

2006
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
    Praxis, 2007, May-02, Volume: 96, Issue:18

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma

2007
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT).
    Diabetes care, 2008, Volume: 31, Issue:1

    Topics: Adolescent; Autoimmunity; Child; Cohort Studies; Diabetes Mellitus, Type 1; Disease Progression; Eur

2008
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2007
Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:12

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycosuria; Hyperglycemia; Insulin;

2000